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Abstract
Membrane Type-1 Matrix Metalloproteinase (MT1-MMP) is a multifunctional protease that
affects cell function via proteolytic and non-proteolytic mechanisms such as promoting
degradation of the extracellular matrix (ECM) or augmentation of cell migration and viability,
respectively. MT1-MMP has been implicated in metastatic progression ostensibly due to its
ability to degrade ECM components and to allow migration of cells through the basement
membrane. Despite in vitro studies demonstrating this principle, this knowledge has not
translated into the use of MMP inhibitors (MMPi) that inhibit substrate catalysis as effective
cancer therapeutics, or been corroborated by evidence of in vivo ECM degradation mediated by
MT1-MMP, suggesting that our understanding of the role of MT1-MMP in cancer progression is
incomplete. To further our understanding of MT1-MMP function, MCF-7 and MDA-MB 231
breast cancer cell lines were created that stably overexpress different levels of MT1-MMP. Using
2D culture, I analyzed proMMP-2 activation (gelatin zymography), ECM degradation
(fluorescent gelatin), ERK signaling (immunoblot), cell migration (transwell/scratch
closure/time-lapse imaging), and viability (colorimetric substrate) to assess how different MT1MMP levels affect these cellular parameters. Matrigel 3D cell culture and avian embryos were
also utilized to examine how different levels of MT1-MMP expression affect morphological
changes in 3D culture, and tumourigenicity and extravasation efficiency in vivo. In 2D culture,
breast cancer cells expressing high levels of MT1-MMP were capable of widespread ECM
degradation and TIMP-2-mediated proMMP-2 activation, but were not the most migratory.
Instead, cells expressing low levels of MT1-MMP were the most migratory, and demonstrated
increased viability and ERK activation. In 3D culture, MCF-7 breast cancer cells expressing low
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levels of MT1-MMP demonstrated an invasive protrusive phenotype, whereas cells expressing
high levels of MT1-MMP demonstrated loss of colony structure and cell fragment release.
Similarly, in vivo analysis demonstrated increased tumourigenicity and metastatic capability for
cells expressing low levels of MT1-MMP, whereas cells expressing high levels were devoid of
these qualities despite the production of functional MT1-MMP protein. This study demonstrates
that excessive ECM degradation mediated by high levels of MT1-MMP is not associated with
cell migration and tumourigenesis, while low levels of MT1-MMP promote invasion and
vascularization in vivo.

Keywords
Matrix Metalloproteinases, MMP-14, Cell migration, 3D culture, Breast cancer, Intravital
imaging
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Chapter 1
1 Introduction
1.1 Cancer Metastasis
Cancer, the collection of related diseases involving uncontrollable cell growth and spread
of abnormal cells in the body, is still a major health problem worldwide despite the progress
made towards reducing its incidence and improving the survival rates of patients [1]. Almost half
of all Canadians will develop cancer in their lifetime, and as such it is the leading cause of death
in Canada followed by cardiovascular disease and respiratory illness [2]. There were about
100,000 new cancer cases for both genders in 2015, with prostate cancer having the highest
incidence in males (23.9%), and breast cancer in females (25.9%) [3]. Beyond the personal costs
afforded by those directly and indirectly affected, cancer also poses a major economic burden on
the Canadian healthcare system, by one estimate costing $3.8 billion in direct healthcare costs in
2008 [4].
Metastasis formation, which is defined as the ability of cancer cells to spread to distant
organs, is responsible for more than 90% of cancer-associated deaths [5]. Metastasis progression
is an extremely complex and multifunctional process whereby cancer cells separate from the
primary tumours and disseminate to distant anatomical sites, via the vascular or lymphatic
system, where they proliferate and form secondary tumours [6]. The progression to metastatic
disease occurs in stages characterized by differential regulation of adhesive interactions and
migratory events, and interactions with non-cancerous cells of the stroma and chemotactic
factors [7]. The stages of metastasis include: development of new blood vessels (angiogenesis);
1

the ‘dissemination’ of cancer cells from the primary tumour; migration through the extracellular
matrix (ECM) surrounding the epithelium; invasion of the basement membrane (BM) underlying
the endothelium of local blood and/or lymphatic vessels (intravasation); transit in the
blood/lymphatic system; arrest and adhesion of the circulating tumour cells to the endothelium of
capillaries at the target organ site; invasion through the endothelial cell layer and surrounding
BM (extravasation); and adaption and growth of secondary tumours at the target organ site (fig
1a) [8-10].

1.2 Traversing the ECM and the Role of Matrix Metalloproteinases
During the multiple stages of metastasis progression, particularly during intravasation
and extravasation, tumour cells must physically traverse the impeding ECM to enter/exit the
circulatory system [11]. The ECM is the heterogeneous non-cellular components of tissues
composed of a network of proteins, glycoproteins, and proteoglycans that includes collagen,
elastin, and fibronectin, amongst others [12]. The role of the ECM is to provide structural
support and modulate cell-signaling cascades via cell surface receptors, predominantly the
integrins [13], to properly compartmentalize tissues while regulating cell fate and function [1417]. Structurally, the ECM can be separated into two types: the interstitial ECM found in
connective tissue, and the basement membrane (BM) underlying tissue epithelia and endothelia
of vessels [18]. The BM is a thin, dense and highly cross-linked ECM composed of an
interwoven mixture of type IV collagen, laminins, nidogen and sulfated proteoglycans beneath
the epithelia and endothelia that surrounds muscles, nerves, adipocytes and smooth muscle cells
(fig 1a, Pre-Cancer) [19]. The ECM in animals can be a highly dynamic structure depending on
developmental stage and tissue location, and as such requires active remodeling of ECM
components by proteolytic degradation or deposition by local epithelial and stromal cells.
2

3

Figure 1. The Matrix Metalloproteinases (MMPs) are thought to function as ECM
remodelers during metastasis formation.
a) Shown is a schematic depicting the process of metastasis of tumour cells derived from an
epithelial cancer. During Pre-cancer (1) there is an organized layer of epithelial cells that are
polarized due to their interaction with the underlying extracellular matrix (ECM). The ECM can
be categorized into two types: the basement membrane (BM) that is a thin dense layer underlying
epithelia/endothelia, and the interstitial ECM that can be found in connective tissue. During
cancer initiation, a carcinogenic mutation occurs that leads to loss of cell cycle control, excessive
proliferation and formation of a primary tumour (2) with accompanying tissue disorganization.
Due to increasing energetic requirements of the tumour, angiogenesis occurs (3) that allows for
vascularization of the tumour and connection to the circulatory system. A subpopulation of
tumour cells will gain the ability to transverse the local ECM and BM to enter the vascular or
lymphatic circulation (intravasation, 4) where they can travel to distant anatomical sites (5).
Cells that survive transit in the circulation can then arrest at the capillary beds of target organs
and exit the circulation (extravasation, 6), transverse the local ECM and BM, and adapt at the
secondary site to eventually form a metastases (7). b) The Matrix Metalloproteinases (MMPs)
are a family of secreted and membrane-type (MT-MMP) proteases that can collectively cleave
all components of the ECM. The predominant role of MMPs during metastasis formation is
thought to be as ECM remodelers, which is shown in the diagram during the process of
extravasation. Excessive MMP activity of cancer cells is thought to allow them to traverse the
BM of circulatory vessels and local tissue prior to metastasis formation at the secondary site.
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The degradation of ECM components is predominantly mediated by the Matrix
MetalloProteinases (MMPs), which are a family of zinc-dependent endopeptidases that can
collectively cleave all components of the ECM [20]. Originally, the MMPs were divided into
collagenases, gelatinases, stromelysins and matrilysins based on their substrate specificity for
components of the ECM [21]. However, it is now known that the MMPs can cleave much more
than ECM components including cell surface receptors, latent ligands, cell adhesion molecules,
and intracellular proteins [22-24]. Due to the continually growing list of MMP substrates, the
current classification for MMPs is rather a sequential numbering system that reflects common
structural features (fig 2). There are six distinct structural classes of MMPs: three are secreted
(typical, gelatin binding, and minimal) and three are membrane-type MMPs (MT-MMPs – type
I, type II, and GPI anchored) [25]. Structurally, the ‘typical’ secreted MMPs (MMP-1, -3, -8, 10, -11, -12, -13, -18, -19, -20 -22, -27, -28) are composed of: an N-terminal signal sequence that
directs them for secretion; a pro-domain that inhibits catalytic activity until it is proteolytically
removed (MMP activation); a catalytic domain with zinc-dependent endopeptidase activity; a
flexible hinge region; and a hemopexin domain that is responsible for substrate specificity,
dimerization, and protein-protein interactions. The ‘minimal’ type of secreted MMPs (MMP-7, 26) are distinct in that they lack a hinge and hemopexin domain, whereas the ‘gelatin binding’
type (MMP-2, -9) have fibronectin and collagen-like protein domain between the catalytic and
hemopexin domains. In addition to the aforementioned domains, type-I MT-MMPs (MMP-14, 15, -16, -24), the most common of the MT-MMPs, contains a transmembrane and short
cytoplasmic domain. Type II MT-MMPs (MMP-23) contains a cysteine array and IgG-like
domain in place of the hemopexin and transmembrane domains, and GPI-anchored MT-MMPs

5
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Figure 2. Matrix Metalloproteinases can be categorized based on domain structure.
The mammalian Matrix Metalloproteinases (MMPs) are grouped into two main classifications
based on domain structure: Secreted and Membrane –type MMPs. Of the secreted MMPs, the
‘minimal’ types are composed of a signal peptide (SP) that directs them for secretion, a prodomain that requires removal for proteolysis, and a catalytic domain with endopeptidase activity.
In addition to the aforementioned domains, ‘typical’ MMPs also contain a flexible hinge region,
and a hemopexin-like domain that dictates binding and substrate specificity. ‘Gelatin binding’
secreted MMPs also contain fibronectin-like repeats, and a collagen-like domain. ‘Type I’
membrane-type MMPs are directed to the cell membrane by the N-terminal signal peptide, and
contain a transmembrane and short cytoplasmic domain in addition to the domains of the
‘typical’ MMPs. ‘Type II’ membrane-type MMPs possess a cysteine array and IgG-like domain
in place of the hemopexin-like, and transmembrane and cytoplasmic domains. GPI anchored
membrane-type MMPs are anchored into the membrane by a GPI anchor and lack a cytoplasmic
domain .

7

(MMP-17, -25) contain a GPI-anchor, in place of the hemopexin, transmembrane and
cytoplasmic domains.
Since MMPs represent a large family of potent proteolytic enzymes, their activity must
be tightly regulated to properly mediate ECM remodeling and maintain homeostasis. The
expression of MMPs is temporally and spatially regulated at the level of transcription by various
growth factors, cytokines and chemokines [21], and also regulated at the post-translational level
via multiple mechanisms. All MMPs are synthesized as zymogens with an inhibitory pro-domain
that inserts into the catalytic site thus preventing access to substrates and ECM degradation. The
proteolytic removal of this domain is necessary to activate MMPs and allow for substrate
degradation, and thus represents the primary mechanism of post-translational regulation [26].
The secreted MMPs are activated by removal of the pro-peptide domain by other active
proteases, including serine proteinases such as chymase and trypsin, or other already active
MMPs [25, 27]. The MT-MMPs are reported to be activated intracellularly prior to membrane
placement by the proprotein convertase, or furin, as they contain the conserved furin target
sequences RXKR or RRKR between the pro- and catalytic domains [28, 29]. However, the
mechanism of MMP activation in general is a contentious point in the literature, as the mode of
activation of most MMPs is more presumed than proved, and the in vivo mechanism for
activation of most proMMPs is unknown [30]. Evidence of our incomplete understanding of
MMP activation is the proof that complete deletion of the furin target sites from MT1-MMP does
not affect its activation [31], indicating the possible role of yet unknown MMP activation
mechanisms.
Once the prodomain has been removed and MMPs are active, their proteolytic activity
can be regulated by the secreted Tissue Inhibitors of MetalloProteinases (TIMPs) [32]. The
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mammalian TIMP family contains four members (TIMPs 1-4) that are composed of an Nterminal MMP inhibitory domain, and a C-terminal domain that has distinct functions depending
on the TIMP [33]. The TIMPs share the common feature that they are the endogenous inhibitors
of MMPs and inhibit their proteolytic activity by forming noncovalent 1:1 stoichiometric
complexes that are resistant to heat denaturation and proteolytic degradation. Although all
TIMPs inhibit MMP activity, TIMPs differ in their expression pattern, solubility, and binding
affinities with the different MMPs. TIMP-1, TIMP-2 and TIMP-4 can be found in soluble forms
in the extracellular milieu, whereas TIMP-3 is strictly found tightly bound to ECM components
[34, 35]. The expression patterns of the TIMPs is regulated at the level of transcription by
various factors for the controlled inducible expression of TIMPs that results in differential
temporal and spatial expression patterns, with the exception of TIMP-2 which demonstrates a
constitutive expression pattern in all tissues [21]. Although TIMPs were originally characterized
as MMP inhibitors, it is now known that TIMPs are multifunctional proteins that can affect
different cellular processes by using their C-terminal domain to interact with cell surface
receptors to induce intracellular signaling cascades that have been shown to promote cell cycle
arrest and affect cell migration [36-38].
Although it has become increasingly clear that MMPs and TIMPs have other biological
functions in addition to ECM homeostasis, the presumed role of these two protein families
during metastasis progression continues to be as ECM remodelers (fig 1b). This presumption
emerges from the fact that during metastasis progression there is a requirement for tumour cells
to traverse the interstitial ECM and BM during the processes of intravasation and extravasation
[11], and given the fact that MMPs can degrade all ECM components, created a longstanding
idea that the role of MMPs in carcinogenesis is to clear a path through the ECM so tumour cells
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can spread to distant organs [30, 39]. This claim is supported by numerous studies conducted in
the past two decades that demonstrate two key concepts unequivocally: there is increased
expression of MMPs in primary tumour tissues [40-48], and interfering with the functions of
certain MMPs results in reduced tumourigenicity [49-62]. Additionally, MMP research in the
cancer field has yielded valuable insight into the cellular molecular mechanisms regarding
MMPs synthesis, transport, function and dynamics [24, 28, 53, 63-77], but has generated few
solid mechanisms, especially using in vivo models and clinical samples [19, 30, 78], regarding
the true role of MMPs in tumourigenicity, and whether they actually play an important role in
this process. The presumed role of MMPs in cancer progression is best exemplified by the
research regarding the complex multifaceted contribution to tumourigenesis of MT1-MMP,
MMP-2 and MMP-9 [23, 79].

1.3 MT1-MMP is a Multifunctional Protease Involved in
Tumourigenesis
Historically, research on MMPs has predominantly focused on the gelatinases, MMP-2
(gelatinase A or GelA) and MMP-9 (GelB), as the number of studies reporting MMP-2 and -9
function are log-fold higher in number than for other MMPs [30]. However, this leads to the
misconception that MMP-2 and -9 are the most biologically important MMPs, which is not the
case, and rather these two MMPs are the most reported because they are measured the most
frequently due to gelatin zymography. Gelatin zymography is an SDS-PAGE based technique
that uses a gel copolymerized with gelatin which allows for the detection and visualization of
MMP-2 and -9 protein in situ by virtue of their ability to degrade gelatin [80]. This became the
preferred approach to detect these MMPs before the availability of antibodies that detect both
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pro- and active forms of MMP-2/-9 [81]. Therefore, the sheer amount of studies of MMP-2/-9
function stems from the ease and inexpensiveness of detecting these MMPs using gelatin
zymography.
As mentioned, all MMPs are synthesized as inactive zymogens that require activation via
removal of the pro-domain. Since gelatin zymography allowed for accurate and inexpensive
detection of the isoforms (pro- and active) of MMP-2 and -9, the mechanisms responsible for the
activation of these gelatinases could be investigated. This lead to the discovery of the only bona
fide, well-characterized and replicable activation mechanism for any MMP: the TIMP-2-assisted
activation of proMMP-2 by MT1-MMP at the cell membrane [82]. MT1-MMP is a type-I MTMMP that is anchored at the cell membrane by a hydrophobic transmembrane domain and also
contains a short intracellular cytoplasmic domain [70]. TIMP-2 is the only constitutively
expressed TIMP that also demonstrates the highest affinity towards MT1-MMP and MMP-2, and
thus is essential to control the proteolytic activity of these two MMPs [83]. However, TIMP-2
also shares an interesting relationship with MT1-MMP and MMP-2, as instead of inhibiting these
proteases, it can also act as an adapter protein critical for the activation of proMMP-2 when
TIMP-2 is present at low levels. In this activation process, extracellular TIMP-2 binds the
hemopexin domain of secreted proMMP-2 using the non-inhibitory C-terminal domain, thereby
creating a molecular complex where the inhibited catalytic site of proMMP-2 is physically
separated from the free N-terminal domain of TIMP-2 [84]. This molecular complex composed
of TIMP-2:proMMP-2 can then insert itself between dimerized active MT1-MMP molecules at
the cell surface due to the free N-terminal domain of TIMP-2 being able to bind to the catalytic
site one of the dimerized MT1-MMP molecules thereby inhibiting it. As a result of this binding
mode, the proMMP-2:TIMP-2 complex is oriented in a way that exposes the pro-domain of
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proMMP-2 to the catalytic site of the uninhibited dimerized MT1-MMP that can then
proteolytically cleave the pro-domain of MMP-2 releasing the active gelatinase [85]. The
activation of proMMP-2 by the cooperation of TIMP-2 and MT1-MMP is the perfect example
regarding the pleiotropy of MMPs and TIMPs, as it demonstrates that MMPs can cleave nonECM components, and that TIMPs can act as promoters, as well as inhibitors, of MMP activity.
The discovery that MT1-MMP is necessary for proMMP-2 activation, and thus can
exacerbate ECM degradation, along with the aforementioned presumption that the role of MMPs
during cancer progression was to facilitate a path through the ECM, lead to the development of
chemical agents that inhibit the catalytic activity of MMPs (MMP inhibitors – MMPi) as anticancer therapeutics. These therapeutic agents demonstrated value in vitro and in animal models
but were ineffective in human clinical trials, in some cases causing serious adverse effects, and
have continued to be a persistent failure as a cancer therapy for the past two decades [86-93].
The failure of these MMPis generated a call to action to appreciate and elaborate on the nonproteolytic functions of MMPs, as the immediate explanations as to why MMPis were ineffective
was the functional redundancy amongst the MMPs (which to date has not been resolved), and/or
that they exerted their biological function through mechanisms that do not involve proteolysis of
ECM components or that are completely non-proteolytic in nature. Similar to the situation
regarding MMP-2 and -9 studies, the discovery of MT1-MMP mediated proMMP-2 activation,
along with the failure of MMPis, created the necessary momentum for the research community
to turn its attention to the ECM independent functions of MT1-MMP [94], and as such the
amount of publications devoted to MT1-MMP are disproportionate in number compared to the
other MT-MMPs [95], and may not reflect the biological importance of MT1-MMP [30]. Due to
research conducted in the past decade, it is now known that MT1-MMP is indeed a

12

multifunctional membrane protease capable of functions independent of ECM remodeling or
catalytic activity, affecting varied biological processes including migration, viability,
metabolism, and induction of intracellular signaling [96].
MT1-MMP has been shown to increase the migratory ability of different types of cancer
cells, in some cases due to MT1-MMP overexpression alone [31, 49, 97]. Reports have shown
that MT1-MMP overexpression increases the migration potential of MCF-7 breast cancer [31],
MG-63 osteosarcoma [98], COS-1 [49], and COS-7 cells [97]. Currently, there is limited
evidence regarding the mechanism behind MT1-MMP mediated migration augmentation, with
some reports showing that co-localization and processing of the cell adhesion molecule CD-44
[98], or increased MAPK signaling via ERK1/2 [97, 99], is responsible for increased migration
of MT1-MMP positive cells. In one of the latter reports, the authors showed that increased
migration as a result of MAPK activation does not depend on proteolytic activity, as high levels
of TIMP-2 or a proteolytically-inactive mutant of MT1-MMP can still induce ERK1/2
phosphorylation and increase migration of MCF-7 breast cancer cells [99]. In addition to
migration promotion, MT1-MMP can also mediate viability of cancer cells, particularly during
serum-free incubation without pro-survival signals. It has been demonstrated that overexpression
of MT1-MMP in MT1-MMP deficient breast cancer cells maintains a proliferative phenotype
when cultured in low-serum conditions [99], and also protects cancer cells from apoptosis via the
AKT pathway when cultured in serum-free conditions [100]. Similar to migration promotion,
apoptosis protection mediated by MT1-MMP did not require its proteolytic activity, as treatment
with TIMP-2 was optimal to promote survivability, which could also be mediated by a
catalytically inactive MT1-MMP.
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A novel and unanticipated function of MT1-MMP was recently reported whereby MT1MMP can initiate and maintain the “Warburg effect” in both macrophages and cancer cells. The
“Warburg effect” or “glycolytic switch” is a hallmark of malignant tumours that is characterized
by increased aerobic glycolysis during normoxia (normal oxygen tension) [101]. This effect is
mediated by the transcription factor hypoxia inducible factor-1 (HIF-1), which is regulated by
post-translational modifications that make this protein liable to degradation in normoxic
conditions and stable in hypoxic conditions [102]. Therefore, when cells sense hypoxic
conditions, HIF-1 is stable and translocates to the nucleus to increase the expression of
glycolytic-related genes to meet with cellular energy requirements in low oxygen conditions. The
distinction between functional HIF-1 in normal physiology and the “Warburg effect” during
tumour progression is that in the Warburg effect HIF-1 is stable and functioning despite normal
oxygen tension, and as such it is still incompletely understood how HIF-1 is stabilized in
normoxic conditions [103]. To further understand HIF-1 function, a research group used
macrophages as their cell model since these cells are an important component of the immune
system and rely predominantly on aerobic glycolysis to produce ATP [104]. This group found,
unexpectedly, that macrophages lacking MT1-MMP produced considerably lower levels of ATP
than wild-type cells. The authors go on to demonstrate that the cytoplasmic domain of MT1MMP can bind to FIH-1 (factor inhibiting HIF-1), which leads to its inhibition (and thus
stabilization of HIF-1) by its recently identified inhibitor, Mint3/APBA3. In follow-up work, the
authors used a variety of cancer cells to show that tumour cell lines that endogenously express
MT1-MMP exhibited increased glycolytic activity, and that overexpression of MT1-MMP in
MT1-MMP deficient cells is sufficient to induce the Warburg effect [50]. Importantly, using
cancer cells, these authors demonstrated that HIF-1 stabilization by MT1-MMP is not dependent
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on the its proteolytic activity, and this effect could be mediated solely by transfection with the
cytoplasmic domain of MT1-MMP, again demonstrating that MT1-MMP is multifunctional and
does not need proteolytic activity to exert its biological function (fig 3). Additionally, the
aforementioned report also demonstrated in vivo that treating MT1-MMP positive tumours with a
MT1-MMP cytoplasmic domain (CD) peptide suppresses aerobic glycolysis and tumour growth
in a dominant-negative fashion, which strongly suggests a substantial non-proteolytic role for
MT1-MMP in tumourigenesis.
Although originally characterized as a potent initiator of ECM remodeling, it is now
accepted that MT1-MMP has many functions beyond degradation of ECM components, for
which the proteolytic activity does not seem to be necessary. However, with this mind, the role
of MT1-MMP in mediating cell function and cancer progression remains unclear, and potentially
more cofounding than ever since the known varied functions of MT1-MMP make it difficult to
delineate the relative contributions of these functions to tumourigenicity. Recently, efforts have
been made to understand the individual functions of MT1-MMP and their relation to cell
invasion and tumorigenic potential. Strongin et al (2013) isolated an antibody that binds MT1MMP in such a way that it does not sterically inhibit the catalytic site of MT1-MMP, but does
interfere with TIMP-2 binding, and thus can completely inhibit TIMP-2-assisted proMMP-2
activation [105]. Although this antibody is effective at inhibiting proMMP-2 activation, it is not
effective at decreasing migratory potential of MT1-MMP positive breast cancer cells, and to date
has not been applied to in vivo models or used in clinical trials.
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Figure 3. MT1-MMP is a multifunctional protease that can affect different processes in
distinct cellular compartments.
MT1-MMP is synthesized in the nucleus, translated in the cytoplasm, and presumably activated
intracellularly at the golgi by the proprotein convertase Furin that removes the pro-domain of
MT1-MMP. During intracellular processing, MT1-MMP can induce stabilization of transcription
factor HIF-1 (a) thereby increasing expression of glycolytic genes and mediating the Warburg
effect. Active MT1-MMP is then anchored in the plasma membrane where it can degrade its
respective substrates, and where it can be inhibited by the TIMPs, particularly TIMP-2 which can
binds its catalytic domain and block access to substrates (b). In addition to MT1-MMP
inhibition, TIMP-2 can also act as an adapter protein to proMMP-2, which aids in its activation
at the cell surface by dimerized MT1-MMP (c), and exacerbates ECM remodeling. TIMP-2 has
also been shown to interact with MT1-MMP at the hemopexin domain where it can induce ERK
and AKT intracellular signaling cascades that have been shown mediate increased migration and
apoptosis protection, respectively. MT1-MMP has also been shown to affect cell motility by
localizing to cellular structures marked by cytoskeletal protrusions, such as lamellopodia or
filopodia that are crucial for lateral cell migration (e), or invadopodia which are necessary for
ventral cell invasion through an impeding ECM barrier (f).
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1.4 Research Project
Despite what is known about the individual functions of MT1-MMP, how these different
functions integrate to mediate cell behavior and tumourigenesis remains poorly understood. The
goal of my PhD research project was to understand the role of MT1-MMP in tumourigenicity by
overexpressing MT1-MMP and analyzing appropriate cellular parameters to determine their
contribution to a metastatic phenotype. To accomplish this goal I used three different
experimental platforms: 2D culture, 3D Matrigel culture, and in vivo ex-ovo avian embryos, and
two cell models: MCF-7 and MDA-MB 231 breast cancer cells.
MCF-7 cells are breast cancer cells that are MT1-MMP deficient, non-migratory and
non-tumorigenic [40, 106]. In contrast, MDA-MB 231 breast cancer cells endogenously produce
MT1-MMP, and are migratory and tumorigenic [41, 66]. Using these two different cell lines, I
created three different clonal cell lines of each that express different levels of MT1-MMP. In 2D
culture, I examined how different levels of MT1-MMP expression alter proMMP-2 activation,
ECM degradation, ERK signaling, cell migration and viability. Using 3D Matrigel culture [107],
I analyzed how different levels of MT1-MMP affected morphological changes associated with an
invasive phenotype. Lastly, I conducted in vivo assays using avian embryos to examine the
potential of the MT1-MMP expressing cell lines to form vascularized tumours [108] and
extravasate out of the vasculature [109], two parameters related to tumourigenicity and
metastasis, respectively.

1.5 Hypothesis
I hypothesize that in 2D culture, the different functions of MT1-MMP will correlate with
the expression level of MT1-MMP in breast cancer cells. Therefore, I expect cells that express
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the highest level of MT1-MMP to demonstrate the highest increase in proMMP-2 activation,
ECM degradation, ERK signaling, cell migration, and viability, in contrast to MT1-MMP
deficient cells that will demonstrate baseline activation of these cellular activities. Furthermore, I
hypothesize that breast cancer cells demonstrating excessive ECM degradation, and increased
migration and viability will display an invasive metastatic phenotype in 3D culture and in vivo. I
expect breast cancer cells expressing the highest levels of MT1-MMP to demonstrate a
protrusive phenotype in 3D culture, indicative of an invasive phenotype, and increased ability to
form vascularized tumours and extravasate out of the vasculature in vivo.
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Chapter 2

2 Materials and Methods
2.1 Cell culture
MCF-7, MDA-MB 231 and HS578t human breast cancer cell lines were obtained from
the American Type Culture Collection (Manassas, VA). Cells were maintained in DMEM/F-12
media (Thermo Fisher) supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml
streptomycin, and incubated at 37oC and 5 % CO2.

2.2 cDNA clones and reagents
Human MT1-MMP (sc116990), TIMP-2 (sc118083) and MMP-2 (sc321560) cDNA
clones were purchased from Origene and subcloned into the vector pcDNA 3.3 (Thermo Fisher).
The generation of the ALA+TIMP-2 cDNA construct in pcDNA 3.3 is described in Walsh et al.,
2012 [110]. The following reagents were used: Recombinant human TIMP-2 and 4aminophenylmercuric acetate (APMA) (Sigma-Aldrich), BB-94 (Batimastat), U-0126, and AKT
inhibitor IV (Santa Cruz), and Furin inhibitor II (Millipore).

2.3 Antibodies
For immunoblot analysis, the following primary antibodies were used: MT1-MMP
(1:1000, AB6004, Millipore); MT1-MMP (1:1000, AB51074, Abcam); Phospho-ERK1/2
(1:2000, D13.14.4E), ERK1/2 (1:2000, 137F5) (Cell Signaling Technology); TIMP-2 (1:1000,
3A4), β-Actin (1:1000, C4), and phospho-histone-3 (PH3) (1:5000, C1513) (Santa Cruz). Goat
anti-mouse IgG (H+L) (Bio-Rad) and goat anti-rabbit IgG (H+L) (Thermo Fisher) HRP
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conjugates were used as secondary antibodies (1:10000). For immunofluorescence analysis, the
anti-MT1-MMP antibody AB6004 (1:200) was used, along with anti-rabbit-IgG-Alexa488 or
Alexa594 (Thermo Fisher) as secondary antibodies (1:400).

2.4 Transfection and generation of stable cell lines
MCF-7 and MDA-MB 231 cells were seeded at a density of 5x105 cells/ml and incubated
for 24 hours in DMEM/F-12 with 10% FBS. Following incubation, cells were transfected with
Lipofectamine 2000 (Thermo Fisher) according to the manufacturers instructions. For transient
transfection experiments, cells were incubated for 24 hours after transfection and then utilized
for experiments.
Stable cell lines were generated by transfection of cells with the respective cDNAs in the
vector pcDNA 3.3, which contains a neomycin mammalian selection marker. Following
transfection, cells were split 1:1000 and incubated in media containing 1 mg/ml G-418 (VWR).
Individual colonies were selected after four weeks of incubation in selection media and expanded
to assay for the levels of MT1-MMP by qPCR and immunoblotting. Stable cells lines expressing
an shRNA sequence targeting MT1-MMP in the vector pRS (TR311445, Origene) were
generated in the same manner except using puromycin (2 μg/ml) as the selection antibiotic.
For zsGreen infection, cells were seeded at ~ 40% density in a 6-well cell culture dish in
3 ml of media with a final concentration of 8 μg/ml polybrene and infected with 250 μL of virus.
For virus production, the pLVX-ZsGreen1-N1 lentiviral plasmid was used. Twenty-four hours
post-infection, the media containing virus was removed and replaced with puromycin selection
media (2 μg/ml) for three days of incubation to select for infected cells.
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2.5 Generation of MMP-2, TIMP-2 and ALA+TIMP-2 conditioned
media (CM)
Conditioned media (CM) containing high levels of MMP-2, TIMP-2, and ALA+TIMP-2
protein were created by transfecting MCF-7 cells with cDNA constructs coding for the
respective proteins. Following a 24-hour incubation post-transfection, transfected cells were
washed with phosphate buffered saline (PBS) and incubated in DMEM/F12 media without FBS
for 24 hours. The serum-free CM were then collected, aliquoted and stored for later use.
Conditioned media from mock-transfected cells were used as a control.

2.6 Quantitative Real-Time PCR
RNA was collected from cells using the RNeasy Kit (Qiagen) and cDNA was synthesized
from 1 μg of RNA using qScript cDNA supermix (Quanta). MT1-MMP mRNA levels were
assayed by qPCR using PerfeCta SYBR Green Supermix (Quanta) and a CXF connect real time
system with CFX manager software (Bio-Rad). mRNA levels were quantified by the ΔΔCT
method and are displayed as fold change relative to parental MCF-7 or MDA-MB 231 cells in
control conditions as indicated in the figure legends. The level of GAPDH mRNA was used as
the internal control. Primers (5’-3’) are as follows: MT1-MMP; F: gcagaagttttacggcttgca, R:
tcgaacattggccttgatctc, MMP-2; F: agctcccggaaaagattgatg, R: cagggtgctggctgagtagat, MMP-9; F:
cctggagacctgagaaccaatc, R: gatttcgactctccacgcatct, GAPDH; F: acccactcctccacctttga, R:
ctgttgctgtagccaaattcgt [40].
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2.7 Immunoblotting
Post-incubation cells were washed 3X with PBS (pH=7.2) and disrupted using lysis
buffer (150 mM NaCl, 1% NP-40, 0.5% NaDC, 0.1% SDS, 50 mM Tris pH 8.0) supplemented
with protease/phosphate inhibitor (Thermo Scientific). Cell lysates were homogenized by
sonication and 15 μg aliquots were analyzed by immunoblotting with MT1-MMP, TIMP-2, pH3, β-actin, pERK1/2 or ERK1/2 primary antibodies, followed by incubation with the appropriate
secondary HRP-conjugated antibody and detection using SuperSignal West Pico
chemiluminescent substrate (Thermo Fisher). Protein lysate from human 21T cell lines was
acquired as previously described [111].

2.8 Gelatin zymography and reverse zymography
Gelatin zymography and reverse zymography were done using samples of serum-free
media (15 μl) as described previously [80]. To assess the proMMP-2 activation ability of MCF-7
cells, which endogenously express very low levels of MMP-2 [41], proMMP-2 CM was added to
cells at a dilution of 30 μl proMMP-2 CM/mL SF media. For reverse zymography, serum-free
medium conditioned for 24 hours by HS578t cells was used as the source of active MMP-2
within the gel, as these cells naturally express high levels of MMP-2 [40].

2.9 Immunofluorescence
Samples for fluorescent gelatin degradation and 3D culture experiments were fixed and
prepared for immunofluorescence according to their respective protocols (see below). MT1MMP primary antibody (AB6004) was detected using anti-rabbit IgG Alexa594 or Alexa488 for
Oregon green-488 gelatin degradation or 3D culture experiments respectively. F-actin was
stained with Alexa633 phalloidin (1:100, Thermo Fisher) and nuclei with 4',6-diamidino-223

phenylindole (1 μg/ml, BioShop Canada). Samples were imaged using a Nikon A1R+ confocal
microscope (1.2 au) with a 20x dry or 60x oil-immersion lens and presented using NIS Elements
software.

2.10 Transwell assays
The migratory potential of cells was measured using 24-well 8 μm pore transwell inserts
(Corning Costar). Cells (2x104) were seeded on the upper chamber of the transwell in serum-free
medium and allowed to migrate towards the bottom chamber which was placed in DMEM/F-12
medium supplemented with 10% FBS. Migration assays were done with uncoated transwell
inserts, whereas invasion assays were done with inserts coated with 20% Matrigel. Cells that
migrated to the lower chamber of the transwell insert were quantified as described previously
[112]. Migrated cells were normalized to MCF-7/MDA-MB 231 parental cells in control
conditions and are presented as a mean percentage ± SEM.

2.11 Scratch closure migration assay
Cells were seeded at a density of 5x105/mL cells in a 35 mm cell culture dish and allowed
to form a monolayer for 24 hours. Following incubation, medium was removed and a scratch (an
area clear of cells) was made down the middle of the cell culture dish with a 100 μl pipette tip.
Cells were washed 3x with PBS (pH 7.2) to remove cell debris and then incubated with fresh
medium. After 2 hours, 10 images were captured down the length of the scratch that represent
the ‘initial’ size of the scratch for that sample. Every 24 hours for 3 days, the same area of the
scratch was imaged to examine how cells migrated to close the scratch. Scratch closure was
quantified using ImageJ 2.0.0 software by measuring the width of the scratch each day and
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normalizing it to the initial size of the scratch. Scratch closure is presented as a mean percentage
of the initial scratch size ± SEM.

2.12 Celltiter96® proliferation assay
Cell viability was inferred by measuring metabolically active cells using Celltiter96®
AQueous One Solution (Promega). Cells were seeded in triplicate (5000 cells/well) onto a 96well cell culture dish in medium supplemented with 10% FBS or serum-free medium.
Immediately after seeding, 20 uL of Celltiter96® AQueous One Solution was added in triplicate
to each sample to obtain an initial reading and ensure that the different cell lines were seeded
equally. The OD at 490 nm was measured using a Bio-Rad model 3550-UV microplate reader
after incubating the cells with the substrate for 2 hours. The substrate was added at the indicated
day intervals and measured in the same way as the initial measurement to create a growth curve
over that span, or to compare the effect of chemical inhibitors on cell viability during prolonged
serum-free incubation.

2.13 Fluorescent gelatin degradation assay
Coverslips were coated with either Oregon Green-488 gelatin (for immunofluorescence
analysis) or gelatin labeled using an Alexa594 protein labeling kit (for live imaging analysis)
(Thermo Fisher) and used to analyze ECM degradation as per Martin et al., 2012 [113].
Immunofluorescence conditions are as described above.

2.14 Three-dimensional (3D) cell culture
Cells (2.5x104) were embedded in 50% Matrigel (Corning Costar) and processed for
immunofluorescence as per Cvetkovic et al., 2014 [107]. To quantify colony morphologies
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observed in 3D culture, five random 50 μm Z-stacks (2 μm step size) were acquired using DIC
microscopy at 10x magnification every day for 5 days post-embedding. For each individual Zstack, invasive features (disseminations and protrusions, see text) were blindly counted and
normalized to the number of circular colonies per field of view. Immunofluorescence procedure
was done as described above using 3% BSA/PBS as the blocking buffer. Single cells (marked by
DAPI), F-actin disseminations, F-actin protrusions and zsGreen protrusions were blindly counted
from 20x 3D volumes and normalized to the number of circular colonies per field of view.

2.15 Live-imaging and timelapse movies
Cells were embedded in Matrigel or seeded on Alexa594 gelatin coverslips as described
above and placed in a live imaging chamber mounted on the stage of a Leica DM16000 B
fluorescent microscope. To analyze the relationship between ECM degradation and migration,
cells stably expressing zsGreen were incubated on Alexa594 gelatin coverslips and imaged at the
same stage position at 10x magnification every 10 minutes for 20 hours. These images were then
compiled into timelapse movies using ImageJ. The zsGreen channel timelapse movies were used
to quantify the migration of individual cells in an automated manner using the ADAPT plugin
for ImageJ [114]. The ADAPT plugin (v1.146) was used with default conditions and the
trajectory visualization output was used to group cells according to the distance migrated. The
Alexa594 gelatin channel was used to manually quantify the percentage of cells that had
degraded the underlying gelatin at different time points. To visualize the dynamics of cells in 3D
culture, cells were embedded in Matrigel and z-stacks (100 μm, 5 μm step size) were acquired at
20x magnification every 30 minutes for 72 hours. Focal panels showing colony features with the
greatest clarity were isolated and compiled into timelapse movies using ImageJ.
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2.16 Avian embryo CAM implantation and extravasation efficiency
assay
For implantation experiments, the superficial layer of the CAM of day 9 chicken embryos
was removed to expose the underlying capillaries [115]. MDA-MB 231, MCF-7 or MCF-7 MT1MMP cell lines stably expressing zsGreen were then resuspended in Matrigel and pipetted onto
the exposed capillaries (5x105 cells in 10 μl Matrigel/embryo). Eight days post-implantation the
resulting tumour was imaged using a fluorescent stereoscope to examine vascularization of the
tumour shown by the presence of non-fluorescent CAM vessels within the zsGreen tumour.
MCF-7 and MCF-7 MT1-MMP cell lines stably expressing zsGreen were used for
intravenous injection into the CAM vasculature of day 14 chicken embryos and extravasation
efficiency was quantified 24 hours post-injection as per Kim et al., 2016 [109].

2.17 Densitometry analysis
Quantitative analysis of immunoblots was done using QuantityOne software (Bio-Rad).
Band intensity was obtained for the pERK and total ERK signal of each sample from three
independent experiments. ERK activation is presented as a ratio between the pERK and the total
ERK band intensity within each sample normalized to MCF-7 cells under control conditions.

2.18 Statistics
Experimental data consists of three biological replicates and is presented as mean ± SEM.
Statistical analysis and graphing was performed using GraphPad Prism version 6.0 (GraphPad
software, La Jolla, CA, USA). One-way ANOVA followed by Tukey’s post-hoc test was used
unless otherwise indicated in the figure legend. Significant differences denoted by asterisks are
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shown versus MCF-7 or MDA-MB 231 parental cells in control conditions unless otherwise
shown in figure. Different levels of statistical significance are denoted by a different number of
asterisks and are as follows: ****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05.
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Chapter 3

3 Results
3.1 Transient Overexpression of Functional MT1-MMP did not Result in
Increased Motility
To begin assessing how MT1-MMP affects the motility of breast cancer cells, I
transiently overexpressed wild-type MT1-MMP in MT1-MMP-deficient MCF-7 breast cancer
cells. Twenty-four hours following transient transfection, MT1-MMP mRNA and protein levels
were analyzed via qPCR and immunoblot, respectively, and proMMP-2 activation ability of
transfected cells via gelatin zymography (fig 4). qPCR and immunoblot analysis showed that
MT1-MMP transfected cells synthesized very high levels of MT1-MMP mRNA (~17,000 fold
relative to mock transfected cells) and produced predominantly the pro- (63 kDa) but also active
isoform (60 kDa), along with degradation forms (44 kDa), of MT1-MMP protein. Gelatin
zymography analysis demonstrated that MT1-MMP transfected cells were capable of proMMP-2
activation, shown by transition from the pro- (72 kDa) to the intermediate (68 kDa) and active
forms (62 kDa) of MMP-2 after transfection. In contrast, mock transfected MCF-7 cells did not
produce any MT1-MMP protein and concurrently were not able to activate proMMP-2, shown
by the presence of only proMMP-2 (control) in the gelatin zymography analysis. To further
verify the functionality of transiently produced MT1-MMP protein, I performed an additional
gelatin zymography analysis after treating transfected cells with of low levels (100 ng/ml) of
recombinant TIMP-2 which was expected to enhance activation of proMMP-2 mediated by
MT1-MMP (fig 5a). Parental MCF-7 cells, which do not secrete endogenous proMMP-2, did not
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Figure 4. Transient transfection of MT1-MMP in MCF-7 breast cancer cells resulted in
high levels of functional MT1-MMP protein.
qPCR, immunoblot, and gelatin zymography (zymo) analysis of MT1-MMP mRNA, protein
levels, and proMMP-2 activation ability, respectively, of MCF-7 breast cancer cells transiently
transfected with MT1-MMP compared to mock transfected cells (control). Immunoblot analysis
(AB6004) showed pro- (63 kDa), active (60 kDa), and degradation forms (44 kDa) of MT1MMP protein in MT1-MMP transfected MCF-7 cells. β-actin was used as a loading control.
Gelatin zymography analysis showed that MCF-7 cells transiently transfected with MT1-MMP
were capable of activating proMMP-2 after 24 hours of incubation as shown by intermediate and
active forms of MMP-2.
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Figure 5. Transient transfection of MT1-MMP in MCF-7 cells resulted in TIMP-2-mediated
proMMP-2 activation, but not increased ERK signaling or cell motility.
(a) Gelatin zymography analysis of MCF-7 cells transiently transfected with MT1-MMP and
incubated for 12 hours with serum-free media (SF, top gel) or MMP-2 conditioned media (CM,
bottom gel). Lanes 1 and 2: Controls showing proMMP-2 chemically activated by APMA. Lanes
4 and 6: Recombinant TIMP-2 (rTIMP-2) was added at 100 ng/ml to enhance MT1-MMPmediated proMMP-2 activation. (b) Immunoblot analysis of MT1-MMP transfected cells
showing pERK1/2 levels. Total ERK1/2 was used as a loading control. (c) Transwell migration
and invasion assays of MCF-7 cells transiently transfected with MT1-MMP. Number of
migrated/invaded cells were normalized to control MCF-7 cells and expressed as a mean
percentage ± SEM (ns, p > 0.05 by student’s t-test).
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increase MMP-2 production after transfection with MT1-MMP, as determined by gelatin
zymography (fig5a, top gel).
To analyze the ability of MCF-7 cells to activate proMMP-2, diluted proMMP-2
conditioned medium (CM) was added that was generated by transfection of MCF-7 cells with a
construct coding for constitutively expressed MMP-2. Since MCF-7 cells are MT1-MMP
deficient, they are not capable of activating proMMP-2 and thus MMP-2 protein in this CM is
predominantly present in the pro- form (fig 5, lane 1), which was confirmed by chemical
activation with 4-aminophenylmercuric acetate (APMA) that completely activates proMMP-2 in
the CM, as shown by the presence of only the active form after treatment (fig 5, lane 2).
Addition of proMMP-2 conditioned media to transfected cells demonstrated that MT1-MMP
overexpression activated proMMP-2 after 12 hours of incubation, shown by the presence of an
intermediate band, and this activation was enhanced by the addition of low levels of recombinant
TIMP-2 that resulted in the presence of more active MMP-2 isoform (fig 5a, bottom gel).
Following confirmation of the functionality of transfected MT1-MMP protein, it was then
examined if MCF-7 cells transiently transfected with functional MT1-MMP demonstrated
increased ERK activation and a corresponding increased in motility. To examine ERK activation,
ERK1/2 phosphorylation was analyzed by immunoblot, whereas migration and invasion were
measured using transwell assays where the transwell insert was uncoated (migration) or coated
with 20% Matrigel which acts as an impeding ECM barrier (invasion). Differing from published
reports [31, 49, 99] there was no difference in ERK activation, (fig 5b) or migration and invasion
(fig 5c, ns > 0.05) in MCF-7 cells that produced functional MT1-MMP protein after transient
transfection.
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To test whether the very high (~17000 fold) levels of MT1-MMP expression achieved
using transient transfection was a factor behind the discrepancies between my observation and
other reports, I created clonal MCF-7 cell lines that stably express significantly different levels
of MT1-MMP by neomycin selection and expansion of resistant colonies after transfection (fig
6). These cell lines, MCF-7 MT1-MMP C1, C2, and C3 cells (hereby referred to as C1, C2 or C3
cells), significantly differ in their stable expression of MT1-MMP transcript from high (C1,
~2,500 fold compared to MCF-7 parental cells), medium (C2, ~1,100 fold) to low (C3, ~11
fold) as determined by qPCR analysis (fig 6a). Immunoblot analysis of these MCF-7 MT1-MMP
cell lines showed that both pro- and active- isoforms of MT1-MMP protein were detected in C1
cells, whereas the active isoform was predominantly detected in C2 cells and no MT1-MMP
protein could be detected by immunoblot in C3 cells (fig 6b). To confirm the functionality of
MT1-MMP protein produced by MCF-7 stable cell lines, I incubated these cells with proMMP-2
CM alone, or in combination with recombinant TIMP-2 (rTIMP-2, 100 ng/ml), or rTIMP-2 and
the panMMP inhibitor BB94 (10 μM), and assessed proMMP-2 activation via gelatin
zymography after 6 or 12 hours of incubation (fig 6c). Cell lines where active MT1-MMP was
detected via immunoblot (C1 and C2 cells) were capable of activating proMMP-2 in a timedependent manner, as there were higher levels of intermediate and active MMP-2 after 12 hours
of incubation compared to 6 hours for these cell lines. As expected, proMMP-2 activation was
enhanced by low levels of recombinant TIMP-2, shown by higher levels of intermediate and
active MMP-2 when TIMP-2 was added. Additionally, proMMP-2 activation was completely
inhibited by addition of BB94, which taken together, confirms production of functional MT1MMP protein in MCF-7 MT1-MMP cell lines.
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Figure 6. Three MCF-7 cell lines, C1, C2 and C3, stably produce different levels of MT1MMP.
(a) qPCR analysis of MT1-MMP mRNA from MCF-7 MT1-MMP cells lines (C1, C2, and C3)
that stably express different levels of MT1-MMP. Different letters indicate significant
differences at p ≤ 0.05 by one-way ANOVA, Tukey’s post-hoc test. (b) Immunoblot analysis
(AB51074) showing pro- (63 kDa), active (60 kDa), and degradation forms (44 kDa) of MT1MMP protein in MCF-7 MT1-MMP cell lines. β-actin was used as a loading control. Lower half
of blot is digitally transformed to clearly shown degradation bands. (c) Gelatin zymography
analysis of MCF-7 MT1-MMP cell lines incubated for 6 or 12 hours with either MMP-2 CM
alone, or in combination with rTIMP-2 at 100 ng/ml, or rTIMP-2 and BB94 (10 μm).
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To confirm that C3 cells produced MT1-MMP protein (poorly detectable by immunoblot)
I used an imaging approach whereby cells were seeded on poly-L-lysine (fig 7) or Oregon-green
488 gelatin coated coverslips (fig 8) and examined using immunofluorescence for MT1-MMP
protein presence, and degradation of the underlying ECM when plated on fluorescent gelatin
[113]. Immunofluorescence analysis on poly-L-lysine coverslips demonstrated that MCF-7 cell
lines overexpressing MT1-MMP contain cytoplasmic MT1-MMP protein, including C3 cells
which show punctate MT1-MMP signal localized at the cell periphery (fig 7). MDA-MB 231
breast cancer cells were also used in this analysis to compare MCF-7, C1, C2 and C3 cells to a
cell line demonstrated to express naturally increased levels of MT1-MMP (fig 8). Quantification
of fields of view acquired at 20x magnification demonstrated no detectable cytoplasmic MT1MMP immunological signal nor gelatin degradation in parental MCF-7 cells. In contrast, 84%
and 60% of C1 and C2 cells displayed ECM degradation (gelatin -), respectively, with
approximately 20% of these cells also displaying punctate cytoplasmic immunological signal for
MT1-MMP protein (fig 8b). A low percentage of MT1-MMP C3 cells (~1.5%) showed ECM
degradation, and a higher percentage (~3%) showed a cytoplasmic MT1-MMP signal, although
these increases were non-significantly different than parental MCF-7 cells. MDA-MB 231 breast
cancer cells (which endogenously produce MT1-MMP, see fig 12c below) were not capable of
widespread cell-associated ECM degradation, and only ~6% of cells displayed cytoplasmic
MT1-MMP signal. Analysis of these samples at 60x magnification clearly demonstrated cell
associated ECM degradation mediated by MT1-MMP, as MT1-MMP protein can be detected
overlaying degraded ECM, and co-localized with F-actin puncta (fig 9, orange arrows). This
observation is consistent with the role of invadopodia in ECM degradation as invadopodia are
defined as ventral structures where F-actin and MT1-MMP are concentrated to mediate substrate
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Figure 7. Cytoplasmic MT1-MMP protein is detectable in all MCF-7 MT1-MMP cell lines
MCF-7 MT1-MMP cell lines were incubated on poly-L-lysine coverslips for 24 hours and
processed for immunofluorescence to examine cytoplasmic MT1-MMP. Representative fields of
view are shown at 60x magnification. Panels are composed of an overlay showing the nuclei
(blue), F-actin (red), and MT1-MMP (green), and the MT1-MMP channel below. Inset shows C3
cells that demonstrate punctate signal pertaining to MT1-MMP protein (white arrows). Scale
bars = 100 μm.
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Figure 8. MCF-7 cell lines that express high levels of MT1-MMP demonstrated widespread
ECM degradation.
(a) MCF-7, MT1-MMP cell lines, and MDA-MB 231 breast cancer cells were incubated on
Alexa488 gelatin-coated coverslips for 24 hours and processed for immunofluorescence to
examine cytoplasmic MT1-MMP protein and ECM degradation. Representative fields of view
are shown at 20x magnification. Panels are composed of an overlay showing the nuclei (blue), Factin (red), MT1-MMP (violet), and Alexa488 gelatin (green) signal (top), and the respective
individual channels below. Scale bars = 100 μm. (b) Cells in each sample positive for
cytoplasmic MT1-MMP protein signal (MT1-MMP +) or that demonstrate gelatin degradation
(Gelatin -) were quantified per 20x fields of view and are shown as mean percentage of total
cells per field of view ± SEM.
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Figure 9. MCF-7 cells producing high levels of MT1-MMP formed degradative structures
marked by F-actin puncta.
MCF-7 MT1-MMP cell lines were incubated on Alexa488 gelatin-coated coverslips for 24 hours
and processed for immunofluorescence to examine cytoplasmic MT1-MMP protein and ECM
degradation. Representative fields of view are shown at 60x magnification. Panels are composed
of an overlay showing the nuclei (blue), F-actin (red), MT1-MMP (violet), and Alexa488 gelatin
(green) signal (top), and the respective individual channels below. Orange arrows indicate cells
that have formed cellular structures that have degraded the underlying fluorescent ECM and are
marked by co-localized MT1-MMP/F-actin signal. White arrows indicate cells that have
degraded the underlying gelatin but are devoid of MT1-MMP signal. Scale bars = 100 μm.
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degradation [66]. Interestingly, in all experiments where MT1-MMP was overexpressed, there
were cells that had degraded the underlying ECM that, paradoxically, were devoid of MT1-MMP
protein signal (fig 9, white arrows).

3.2 Low levels of MT1-MMP expression combined with high levels of
TIMP-2 increased the migratory potential of MCF-7 cells via the ERK
pathway
As assays using transient transfection of MT1-MMP demonstrated no change in cell
migration or invasion, I wanted to further examine this migratory effect as well as the potential
role of ERK activation using the stable cell lines that express lower levels of MT1-MMP than
transiently transfected cells. As others have previously shown that TIMP-2 can modulate rapid
(within 15 minutes) ERK activation by MT1-MMP expressing breast cancer cells [99, 116], I
utilized conditioned media (CM) that contained high levels of TIMP-2, or ALA+TIMP-2. These
CMs were generated by transiently transfecting MCF-7 cells with constructs coding for these
secreted proteins and then collecting the CM after incubating transfected cells in serum-free
media. ALA+TIMP-2 is a TIMP-2 mutant that cannot inhibit the enzymatic activity of MMPs as
it contains a non-functional N-terminal domain due to addition of a terminal alanine (hence
ALA+), but which has been shown to still bind cell surface MT1-MMP with the C-terminal
domain and upregulate ERK activation [99, 117]. ALA+TIMP-2 is a useful reagent to analyze
ERK activation mediated by MT1-MMP/TIMP-2 as this mutant TIMP-2 cannot be sequestered
by other active MMPs and thus strongly induces ERK activation by MT1-MMP positive cells.
Analysis of TIMP-2 and ALA+ TIMP-2 protein levels in the CMs via immunoblot showed that
high but equal levels of TIMP-2 and ALA+TIMP-2 are present in the media after transfection,
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whereas reverse zymography analysis demonstrated that only TIMP-2 was capable of inhibiting
MMPs as the TIMP-2 protein was able to inhibit MMPs within the gel (shown by dark bands),
whereas ALA+TIMP-2 protein was not (white bands, indicative of MMP activity) (fig 10a).
Using these CMs, the ability of MCF-7 MT1-MMP cell lines to sequester TIMP-2 protein
from the media was examined by treating these cells with diluted CMs. TIMP-2 levels remained
equal after 15 minutes, but after 12 hours of incubation TIMP-2 levels in the media decreased
corresponding to the level of MT1-MMP expression of the cell line (fig 10b), further confirming
that these cells produced differing levels of functional cell surface MT1-MMP that binds TIMP2. Quantification of TIMP-2 protein in the CMs was performed via immunoblot which
demonstrated that undiluted TIMP-2 CM contains approximately 10 μg/ml TIMP-2 protein (fig
10c). The proMMP-2 activation ability of MCF-7 MT1-MMP cells was also tested by gelatin
zymography and reverse zymography in the presence of increasing levels of TIMP-2 or
ALA+TIMP-2 CM (fig 10d). Only C1 and C2 cells were capable of activating proMMP-2, and
this was enhanced by addition of low levels of TIMP-2 (~ 100 ng/ml, red arrows), but inhibited
by high levels of TIMP-2 (> ~1 μg/ml, blue arrows) [83, 116, 118], consistent with the
observations of others that TIMP-2 at 100 ng/ml is optimal for proMMP-2 activation by MT1MMP expressing cells [119]. ALA+TIMP-2 did not enhance proMMP-2 activation in these cells
consistent with the requirement for both the N- and C-terminal domains of TIMP-2 to act as an
adapter for proMMP-2 during its activation process [85]. Taken together, this analysis confirmed
the functionality of TIMP-2/ALA+TIMP-2 CMs and demonstrated how MCF-7 cells producing
high levels of MT1-MMP protein follow the well-defined mechanism described for MT1MMP/TIMP2 mediated activation of proMMP-2.
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Figure 10. MCF-7 breast cancer cells expressing high levels of MT1-MMP displayed the
well-characterized relationship of TIMP-2-mediated proMMP-2 activation.
(a) To generate TIMP-2 conditioned media MCF-7 cells were transiently transfected with TIMP2 or ALA+TIMP-2 cDNA, and the protein lysate and media were subsequently collected for
analysis using immunoblot (top) and reverse zymography (bottom) to examine TIMP-2 protein
levels. β-actin was used as a loading control. Reverse zymography analysis shows that TIMP-2
inhibits MMP activity (dark bands), whereas ALA+TIMP-2 is devoid of this function (light
bands) due to the non-functional N-terminal domain. (b) Reverse zymography of MCF-7 and
MT1-MMP cell lines incubated for 15 minutes or 12 hours with TIMP-2 or ALA+TIMP-2 CM
diluted 1:100 to measure TIMP-2 levels remaining in the media post-incubation with MT1-MMP
expressing MCF-7 cells. Serum free medium with CM diluted from mock-transfected cells was
used as a control. (c) Immunoblot analysis of serially diluted recombinant TIMP-2 and TIMP-2
CM. The image of the bottom blot is a visually transformed version of the top blot to enhance the
banding pattern for the recombinant TIMP-2 samples. Based on densitometry analysis (not
shown), the concentration of TIMP-2 protein in TIMP-2 CM is estimated to be approximately 10
μg/ml. (d) MCF-7 and MT1-MMP cell lines, C1, C2, and C3, were incubated for 12 hours with
proMMP-2 CM supplemented with increasing dilutions of TIMP-2 or ALA+TIMP-2 CM (1:100;
1 part CM, 100 parts SF media) and then this medium was assayed using zymography and
reverse zymography to assess proMMP-2 activation and TIMP-2 levels, respectively. Low levels
(1:100) of TIMP-2 enhance activation of proMMP-2 by MCF-7 cells expressing high levels of
MT1-MMP (red arrows), whereas high levels of TIMP-2 (Full CM; undiluted) inhibit this
activation process (blue arrows).
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To then examine the level of ERK activation by MCF-7 MT1-MMP cell lines and the
role of TIMP-2 in mediating this process, cells were incubated in media containing either 10%
FBS or in serum-free (SF) media containing different dilutions of TIMP-2 or ALA+TIMP-2 CM.
Phospho-ERK levels were then examined using immunoblotting (fig 9, left) and quantified via
densitometry (fig 11, right). In media containing 10% FBS, only C2 cells had a significantly
higher level of pERK (~8 fold) compared to parental MCF-7 cells. A 12-hour incubation with
TIMP-2 or ALA+TIMP-2 CM demonstrated a significant decrease in ERK activation in C2 cells.
In contrast, a short 15 minute incubation period with CMs demonstrated a significant increase in
ERK activation of C2 and C3 cells, but not C1 cells, particularly with ALA+TIMP-2 treatment.
Additionally, short incubation periods with dilutions of ALA+TIMP-2 CM showed that ERK
activation in C2 and C3 cells, but not C1 cells, is significantly upregulated by high levels of
ALA+TIMP-2 protein. Overall, analysis of pERK levels demonstrated that cells expressing
medium (C2) and low (C3) levels of MT1-MMP demonstrate increased ERK activation that is
upregulated by high levels of TIMP-2 (> ~ 200 ng/ml) and independent of MMP inhibition as
shown by ALA+TIMP-2 treatment.
Since phosphorylated ERK is an active transcription factor, I assayed for changes in gene
expression in MCF-7 MT1-MMP stable cell lines that may correlate with activation of ERK. I
analyzed the mRNA of TIMP-2, MMP-2, and MMP-9 to assess if ERK phosphorylation
correlated with altered expression of these genes, and found that activation of ERK did correlate
with increased expression of MMP-2 and -9. MCF-7 C2 cells, which demonstrated the highest
level of ERK phosphorylation, also demonstrated significantly higher MMP-2 and -9 mRNA
levels than parental MCF-7 cells as determined by qPCR (fig 12a). To better define the role of
elevated pERK levels in C1, C2, and C3 cells, a MEK inhibitor was used (U0126) that inhibits
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Figure 11. MCF-7 cells producing active MT1-MMP and exposed to high levels of TIMP-2
showed rapid activation of the ERK pathway.
Representative immunoblot analysis (left) of ERK1/2 activation after MCF-7 and MT1-MMP
expressing cell lines, C1, C2, and C3, were seeded and incubated for 12 hours or 15 minutes with
media containing 10% FBS or SF media supplemented with different dilutions of TIMP-2 or
ALA+TIMP-2 CM (1:100=1 part CM:100 parts SF media). Total ERK1/2 was used as a loading
control. ERK activation was measured (respective bar graphs on the right) by densitometry
quantification of the pERK1/2 signal and normalization to the total ERK1/2 signal for each
sample. ERK activation is displayed as mean arbitrary units (a.u.) ± SEM.
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Figure 12. MT1-MMP-mediated ERK activation regulates an inverse transcriptional
relationship between MMP-2 and MMP-9 in breast cancer cells.
(a) (Top) Immunoblot analysis of pERK1/2 levels after MCF-7 and MT1-MMP cell lines were
incubated for 24 hours in media containing 10% FBS and supplemented with a vehicle control
(0.1% DMSO) or the MAPK inhibitor U0126 (10 μM). Total ERK1/2 was used as a loading
control. (Bottom) Following incubation, MMP-2 and MMP-9 mRNA levels were quantified via
qPCR and displayed as mean fold change relative to vehicle treated MCF-7 cells ± SEM. (b)
MDA-MB 231 cells were incubated for 24 hours in media containing 10% FBS and
supplemented with a vehicle control (0.1% DMSO) or the MAPK inhibitor U0126 (10 μM).
Following incubation, pERK1/2 and MMP-2/9 protein levels were measured via immunoblot and
gelatin zymography, respectively (left), and MMP-2 and MMP-9 mRNA levels were quantified
via qPCR (right) and displayed as mean fold change relative to vehicle treated MDA-MB 231
cells ± SEM. (c) Immunoblot (AB51074) and reverse zymography analysis comparing MT1MMP, pERK and TIMP-2 protein levels between MCF-7, MDA-MB 231, and HS578t breast
cancer cells. β-actin and total ERK1/2 were used as loading controls. (d) qPCR analysis of
endogenous MT1-MMP, MMP-2, and MMP-9 mRNA levels from MCF-7, MDA-MB 231 and
HS578t breast cancer cells. mRNA levels are displayed as mean fold change relative to MCF-7
cells ± SEM. (e) Gelatin zymography analysis of MCF-7, MDA-MB 231, and HS578t breast
cancer cells incubated in SF media for 12 hours. Lane 1 shows proMMP-2 CM activated by
MCF-7 C2 cells treated with TIMP-2 CM diluted 1:100 to show proMMP-2 activation as a result
of TIMP-2/MT1-MMP.
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phosphorylation of ERK1/2, with the expectation that expression of these genes would be
decreased following treatment with U0126. Inhibition of ERK phosphorylation by U-0126 (10
μM) demonstrated that ERK activation was indeed responsible for altered transcription of these
genes; however only MMP-9 transcription was decreased to parental levels in C2 cells, whereas
MMP-2 expression actually increased in C2 cells after U-0126 treatment. To confirm that this
“transcriptional switch” of MMP-2/-9 mediated by ERK activation in MT1-MMP positive cells
is not an anomaly related to MT1-MMP overexpression in MCF-7 cells, MDA-MB 231 cells
were also used to perform a similar analysis whereby ERK activation was inhibited and MMP-2
and -9 levels were then examined (fig 12b). MDA-MB 231 cells endogenously produce high
levels of phosphorylated ERK that can be successfully inhibited by incubation with U-0126, as
shown by immunoblot (fig 12b, top left). After incubating MDA-MB 231 cells with U-0126,
MMP-2 and -9 levels were examined via gelatin zymography (fig 12b, bottom left) and qPCR
(fig 12b, right), which demonstrated that ERK inhibition increased MMP-2 and decreased
MMP-9 at the protein and mRNA level, respectively. To further establish this transcriptional
relationship between MMP-2 and -9 in MT1-MMP positive breast cancer cells, the levels of
endogenous MMP-2 and -9 mRNA were examined between MT1-MMP deficient MCF-7 cells
and MT1-MMP positive MDA-MB 231 and HS578t cells. Immunoblot analysis demonstrated
that MDA-MB 231 and HS578t cells produce active MT1-MMP protein in contrast to MCF-7
cells, and that MDA-MB 231 cells produce significantly higher pERK than both MCF-7 and
HS578t cells, although some pERK could be detected from HS578t cells (fig 12c). Reverse
zymography analysis demonstrated that MDA-MB 231 and HS578t cells produce higher and
relatively equal levels of TIMP-2 compared to MCF-7 cells. qPCR analysis confirmed that both
MDA-MB 231 and HS578t cells express significantly higher levels of MT1-MMP than MCF-7
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cells, with HS578t cells expressing significantly lower levels of MT1-MMP compared to MDAMB 231 cells (~100 vs ~170 fold, respectively) (fig 12d). Comparing the levels of MMP-2 and 9 transcripts from MDA-MB 231 and HS578t cells demonstrated that MDA-MB 231 cells
express higher levels of MMP-9, and lower levels of MMP-2, which correlated with the level of
pERK between these cell lines and is consistent with the previous observations. Furthermore,
MMP-2 and -9 protein levels were compared between the three breast cancer cell lines using
gelatin zymography (fig 12e), which demonstrated that MDA-MB 231 cells produce high levels
of MMP-9 protein, and HS578t produce high levels of MMP-2 protein. Importantly, endogenous
MMP-2 and -9 protein secreted by these cells is predominantly found in the pro-form, indicating
that activation of these secreted MMPs does not occur in these cell lines despite production of
active MT1-MMP protein.
After demonstrating that MT1-MMP overexpression does result in activation of
functional ERK in MCF-7 C2 and C3 cell lines, I then examined how TIMP-2-mediated ERK
activation related to the migratory potential of these cell lines. A scratch closure assay was
performed over a span of 3 days which demonstrated that only C3 cells closed the scratch
significantly faster than parental MCF-7 cells, indicating increased migratory ability of C3 cells
(fig 13). Migration was then examined using transwell assays where the cells were incubated in
SF media containing TIMP-2 and ALA+TIMP-2 CMs in the upper compartment and allowed to
migrate towards the lower compartment containing 10% FBS (fig 14a). TIMP-2 CM caused a
significant increase in the number of migrated C2 and C3 cells, while ALA+TIMP-2 CM also
caused a significant increase in the number migrated C3 cells (fig 14a, top). Higher dilutions of
ALA+TIMP-2 CM showed a similar trend whereby only C2 and C3 cells demonstrated a
significant increase in the number of migrated cells (fig 14a, bottom). C1 cells, which express
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Figure 13. MCF-7 cells expressing low levels of MT1-MMP demonstrated increased
migratory potential.
Scratch closure migration assay of MCF-7 MT1-MMP cell lines, C1, C2, and C3, monitored for
3 days. Shown are representative 10x fields of view. The white dotted lines indicate the initial
scratch size; red dotted lines indicate the scratch size at the respective day. Scale bars = 100 μm.
Line graph on the right shows scratch closure quantification that demonstrates significantly
increased migratory potential of C3 cells. Scratch closure is shown as percent closure relative to
initial scratch size ± SEM.
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Figure 14. Low MT1-MMP/high TIMP-2 was optimal to promote migration of MCF-7 cells
via ERK activation.
(a) Transwell migration assays of MCF-7 MT1-MMP cell lines incubated for 48 hours in TIMP2, or ALA+TIMP-2 CM diluted 1:100 (top), or ALA+TIMP-2 CM in increasing dilutions
(bottom). Migration is shown as the percentage of migrated cells relative to MCF-7 cells
incubated in SF media ± SEM. (b) (top) qPCR analysis showing MT1-MMP mRNA from two
cell lines derived from MT1-MMP C3 cells that stably express an shRNA construct targeting
MT1-MMP, and one cell line stably expressing a control scrambled shRNA construct. Different
letters indicate significant differences at p ≤ 0.05 by one-way ANOVA, Tukey’s post-hoc test.
Individual student’s t-tests comparing MCF-7 cells against the C3 SH 1 cell line is also shown.
MT1-MMP transcripts levels are shown as fold change relative to MCF-7 cells ± SEM. (bottom)
Transwell migration assay of MT1-MMP C3 cell lines incubated for 48 hours in either TIMP-2
or ALA+TIMP-2 CM diluted 1:10, or ALA+TIMP2 /U0126 (10 μm). Migration is shown as the
percentage of migrated cells relative to MCF-7 cells incubated in SF media ± SEM.
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the highest level of MT1-MMP, demonstrated an inability to increase migration potential when
incubated with TIMP-2 CMs, and this was consistent with the lack of ERK activation upon
TIMP-2 treatment in these cells. To determine if the enhanced migratory ability of C3 cells was a
result of the relatively low (11 fold) increase in MT1-MMP expression, these cells were
transfected with a construct expressing an shRNA targeting MT1-MMP, and two cell lines were
selected: C3 SH 1, a partial knockdown which displayed a small but significant increase in MT1MMP mRNA level (1.8 fold change p ≤ 0.01) as compared to parental MCF-7 cells, and C3 SH
2, a complete knockdown with 1.1 fold change (ns p=0.62) (fig 14b, top). A cell line was also
derived from C3 cells stably expressing a scrambled control shRNA (C3 SH SCR). Migration of
these C3 cell line variants were assayed during incubation in SF media containing TIMP-2 or
ALA+TIMP-2 CM, or ALA+TIMP-2 CM along with the ERK inhibitor U0126 (10 μM).
Consistent with the previous transwell assays, C3 and control C3 SH SCR cells were
significantly more migratory than parental MCF-7 cells when exposed to high levels of TIMP-2
(> ~1 μg/ml), and this correlated with ERK activation as ALA+TIMP-2/U0126 incubation
attenuated this migration (fig 14b, bottom). This analysis also showed that complete knockdown
of MT1-MMP expression (C3 SH 2) inhibited the TIMP-2-mediated increase in migration,
indicating that MT1-MMP is needed for enhancement of migratory potential via TIMP-2.
Surprisingly, C3 SH 1 cells, which express a small but significant (1.8 fold) increase in MT1MMP transcript levels, demonstrated a similar TIMP-2-mediated increase in migration via ERK
activation. Additionally, I attempted to knockdown MT1-MMP expression in C1 and C2 cells to
rescue migratory potential using the same approach, however, this was unsuccessful using
transfection of shRNA (not shown) presumably because of the excessively high expression of
MT1-MMP in these cells. Taken together, these data demonstrated that TIMP-2 enhancement of
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migratory potential is indeed dependent on MT1-MMP and ERK activation, but low levels (1.8 11 fold) of MT1-MMP expression appear to be optimal to increase migratory ability, whereas
high (> ~1000 fold) MT1-MMP expression does not result in augmented cell migration.

3.3 Low levels of MT1-MMP expression and activity were optimal for
cell viability in serum free conditions
To analyze how MT1-MMP overexpression mediated viability and how this might
explain the different migratory potential of MCF-7 MT1-MMP cell lines, cell viability was
inferred by measuring metabolically active cells using CellTiter 96® AQueous One Solution
each day for 7 days during incubation in media containing 10% FBS or SF media (fig 15), which
represents the two compartments in the transwell assay. In 10% FBS, C1 cells (high MT1-MMP
level) showed a significantly lower viability throughout the 7 days. Conversely C3 cells (low
MT1-MMP level) were significantly more viable from seeding until day 3 (fig 15, top).
Similarly, in SF media C1 cells were less viable than parental MCF-7 cells from seeding until
day 5, whereas C3 cells were significantly more viable during this time (fig 15, bottom). After 6
days of incubation in SF media, all MT1-MMP expressing cells were significantly more viable
than MCF-7 cells indicating that MT1- MMP has an essential role in mediating viability during
prolonged absence of growth factors. To confirm that MT1-MMP was responsible for this
increased viability during SF incubation, the previous analysis was repeated using the C3
knockdown variants (fig 16). Consistent with the previous analysis, only C3 cells had
significantly higher viability at day 3, but by day 6 and 9 all MT1-MMP expressing cell lines
were significantly more viable than MCF-7 cells (fig 16a). Viability measurements of the C3
knockdown variants demonstrated that MT1-MMP is responsible for enhanced viability during
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Figure 15. MCF-7 cells expressing MT1-MMP demonstrated increased viability during
incubation in serum-free conditions.
MCF-7 cells and MT1-MMP cell lines were seeded in 96-well cell culture plates and their
viability was measured every day for seven days using Celltiter96® during incubation in media
containing 10% FBS (top) or serum-free media (bottom). Viability is displayed as mean optical
density (O.D) at 490 nm ± SEM.
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Figure 16. Low levels of MT1-MMP were necessary and optimal for increased survivability
of MCF-7 breast cancer cells to serum-free stress.
(a) Viability of MCF-7 MT1-MMP cell lines, C1, C2, and C2, and C3 SH cell line variants
during incubation in SF media measured every 3 days for 9 days using Celltiter96®. Viability is
displayed as mean optical density (O.D) at 490 nm ± SEM. (b) Immunoblot analysis showing
PH3 protein levels collected from MCF-7 MT1-MMP cell lines and C3 cell line variants
incubated in SF media for 6 days. β-actin was used as a loading control. Bar graph below shows
densitometry analysis of PH3 levels relative to β-actin and normalized to MCF-7 cells ± SEM.
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SF incubation as C3 SH 2 cells, which are MT1-MMP deficient similar to parental MCF-7 cells,
are less viable than other cell lines at day 6, and show the same viability as MCF-7 cells at day 9.
To corroborate these results, cell lysates from MCF-7 MT1-MMP cell lines that were incubated
in SF media for 6 days were analyzed via immunoblot (fig 16b) for the cell proliferation marker
phospho-histone 3 (PH3), and quantified using densitometry (fig 16b, bar graph). All MCF-7
cell lines that expressed significantly higher levels of MT1-MMP than MCF-7 cells showed
higher levels of PH3 after incubation in SF media, particularly C2 cells, which accumulated high
levels of active MT1-MMP protein, and showed significantly higher levels of PH3 than MCF-7
cells.
It was then examined how inhibition of select signaling pathways affected the viability of
MCF-7 MT1-MMP cell lines during prolonged SF incubation to gain insight into the mechanism
behind MT1-MMP-mediated survivability. The chemical inhibitors U0126, BB94, furin inhibitor
II, and AKT inhibitor IV were used to examine their effect on the viability of MCF-7 MT1-MMP
cell lines after 6 days of SF incubation (fig 17). ERK inhibition and AKT inhibition significantly
decreased the viability of all MT1-MMP expressing cells consistent with the observations of
others [99, 100]. Furin inhibitor (which would inhibit intracellular activation of MT1-MMP)
showed a non-significant dose dependent decrease in the viability of cells expressing MT1MMP, a trend not seen in MCF-7 parental cells, indicating that high levels of pro-MT1-MMP
likely negatively mediated viability. Unlike all the other inhibitors that generally decreased
viability, low concentrations of BB94 trended to increase the viability of all MT1-MMP
expressing cells, especially C1 cells which displayed a significant increase in viability after 6
days of SF incubation with 2.5 μM BB94. Taken together, these data demonstrated that MT1MMP mediated survivability to serum-free stress, but that excessive MT1-MMP proteolytic

66

67

Figure 17. Low level of MMP activity was optimal for increased viability of MCF-7 breast
cancer cells to serum-free stress.
Viability of MCF-7 MT1-MMP cell lines was measured after incubation for 6 days in SF media
containing increasing concentrations of U0126, BB94, a furin inhibitor or an AKT inhibitor.
Black asterisks show statistically significant differences between the initial and day 6 viability
within cell lines, and also differences between the day 6 viability of MCF-7 cells compared to
MT1-MMP expressing cell lines. Red asterisks indicate significant differences (p ≤ 0.05) within
cell lines between the day 6 viability in SF media compared to the viability after 6 days of
incubation with the different concentrations of the inhibitors. Viability is displayed as mean
optical density (O.D) at 490 nm ± SEM.
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activity may be counterproductive to increased viability. Furthermore, this analysis also
demonstrated that cell viability has to be considered as a component to the pattern of migration
seen in transwell assays, as C3 cells which were the most migratory are also the most viable,
whereas in contrast C1 cells were the least viable and migratory. Therefore, it is difficult to
delineate the relative contribution of changes in cell proliferation or changes in migratory
capability to the difference in the number of cells quantified in the bottom compartment of a
transwell at the endpoint of the assay.

3.4 MT1-MMP levels did not correlate with migratory potential of breast
cancer cells
Here I present evidence that high MT1-MMP levels (transient transfectants, C1 and C2
cells) did not correlate with the migration of MCF-7 breast cancer cells, as seen using the
transwell migration assay, which I showed also included a substantial cell viability component.
Increased MT1-MMP-mediated viability may have yielded a higher number of cells in the
transwell compartments, which may have resulted in incorrect conclusions about migratory
potential if viability were not considered. To confirm that high MT1-MMP overexpression (>
1000 fold compared to MCF-7 cells) does not result in increased migration, a live imaging
approach was used with automated migration quantification of MCF-7 MT1-MMP cells that
were stably expressing fluorescent zsGreen protein and incubated on Alexa594 gelatin coated
coverslips in control conditions (0.1% DMSO) (fig 18, videos 1-4) and with BB94 (10 μM) (data
not shown). Automated quantification using the ADAPT plugin for ImageJ software [114]
allowed me to track the migration of all individual cells in three independent experiments, which
were then grouped according to their distance migrated (fig 18b, video 5). This analysis showed
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Figure 18. MT1-MMP levels were inversely correlated to the migratory potential of breast
cancer cells.
(a) MCF-7 MT1-MMP cell lines stably expressing zsGreen were seeded on Alexa594-gelatin
(red) coated coverlips in media containing 0.1% DMSO (control) or 10 μm BB94 and incubated
in a live imaging chamber. Each sample was imaged at the same five stage positions every 10
mins for 20 hours to visualize zsGreen cell movement and associated ECM degradation, shown
as black holes devoid of Alexa594 signal (Videos 1-4). Shown are stills of the Alexa594 gelatin
channel and an overlay including the zsGreen cells at time 0 and 20 hours post-seeding of the
control sample (BB94 not shown). Scale bars = 100 μm. (b) Time-lapse videos from (a) were
analyzed using the ADAPT plugin for ImageJ and all individual cells tracked from each cell line
were examined and grouped according to their migration distance from initial point of tracking.
(c) Percentage of cells per field of view from each cell line that degraded the underlying
AlexaFluour594-gelatin at five different time points. MCF-7 and MT1-MMP C3 cells did not
demonstrate degradation of the underlying fluorescent gelatin. (d) Transwell migration assay of
MCF-7, MDA-MB 231, and HS578t breast cancer cells incubated in SF media for 24 hours.
Migration is shown as the percentage of migrated cells relative to MCF-7 cells ± SEM.
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that high MT1-MMP overexpression inhibited migration of MCF-7 cells as a higher proportion
of C1 and C2 cells migrated a shorter distance from the initial point of tracking compared to
parental MCF-7 cells, as 53% and 79% of C1 and C2 cells, respectively, migrated more than 25
μm, compared to 86% of parental MCF-7 cells that migrated the same distance. In contrast, C3
cells did have increased migration ability compared to MCF-7 cells, as 92% of C3 cells migrated
more than 25 μm. Importantly, this 6% increase in migratory ability between MCF-7 and C3
cells does not reflect the increase seen using the transwell assays (20-100% increase), confirming
that there is a cell viability component underlying the number of cells that transgressed to the
bottom transwell compartment. BB94 incubation did not affect the migration of MCF-7 cells or
C2 cells, but did alter the migratory patterns of C1 and C3 cells. Inhibition of MMP activity by
BB94 decreased the migratory ability of C3 cells as 92% of cells migrated more than 25 μm in
control conditions compared to 66% during BB94 incubation. C1 cells, which express the
highest level of MT1-MMP and are the least migratory under control conditions, markedly
improved their migratory potential during BB94 incubation as 73% of cells migrated more than
25 μm (compared to 53% in control conditions). This migration data is consistent with the cell
viability assay during BB94 incubation, as C1 cells saw an augmentation rather than decrease in
viability and migration when MMPs were inhibited, suggesting that excessive MMP activity is
counterproductive to those cellular processes. Analysis of the percentage of cells that degraded
the underlying ECM demonstrated a time-dependent increase in ECM degradation correlated to
high MT1-MMP expression in C1 and C2 cells (fig 18c), confirming functional MT1-MMP
protein production in these cells during the course of this assay. As expected, incubation with
BB94 (10 μM) did not allow for degradation of the fluorescent gelatin by MT1-MMP expressing
cells (not shown). Taken together, this analysis demonstrated that low levels of MT1-MMP
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expression (11 fold compared to parental cells) are optimal for increased migratory ability of
MCF-7 breast cancer cells, whereas high MT1-MMP overexpression (> 1000 fold) does not
increase migration but allows for widespread ECM degradation. To further investigate the
correlation between MT1-MMP expression levels and the migratory potential of cells, I extended
my observations to MDA-MB 231 and HS578T breast cancer cells. Transwell migration assays
demonstrated that MDA-MB 231 and HS578t were significantly more migratory than MCF-7
cells (fig 18d). Importantly, HS578t cells were significantly more migratory than MDA-MB 231
cells even though they express lower levels of MT1-MMP (fig 12).
Having examined MT1-MMP overexpression in MT1-MMP deficient MCF-7 cells, I
then tested how overexpression of MT1-MMP in MDA-MB 231 cells affects the migration of
cells that natively express MT1-MMP and have endogenous migratory ability. MDA-MB 231
MT1-MMP stable cell lines were created in the same manner as the MCF-7 cell lines, and three
were selected which produce the isoforms of MT1-MMP shown via immunoblot (fig 19a).
MDA-MB 231 C1 cells produce pro- and active- MT1-MMP, whereas MDA-MB 231 C2 and C3
produce predominantly active MT1-MMP at higher levels than parental MDA-MB 231 cells.
Transwell migration analysis of these MDA-MB 231 MT1-MMP cell lines showed that
overexpression of MT1-MMP significantly decreased their migratory potential compared to
parental MDA-MB 231 cells (fig 19b). Viability of these cell lines was analyzed in 10% FBS
(top) and SF media (bottom) in the same manner as MCF-7 cell lines to show that MT1-MMP
overexpression significantly inhibited viability, particularly of MDA-MB 231 C1 and C3 cells
(fig 19c). Further, MDA-MB 231 C2 cells, which accumulate high levels of active MT1-MMP
protein, exhibited increased viability in SF media and during prolonged incubation in 10% FBS,
which was consistent with both the PH3 analysis of MCF-7 C2 cells that predominantly produce
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Figure 19. Overexpression of MT1-MMP in MDA-MB 231 cells negatively affected
migration and viability
(a) Immunoblot analysis (AB6004) showing pro- (63 kDA), active (60 kDa), and degradation
forms (44 kDa) of MT1-MMP in MDA-MB 231 breast cancer cells and three MDA-MB 231 cell
lines expressing different levels of MT1-MMP. β-actin was used as a loading control. Lower half
of blot is digitally transformed to clearly shown degradation bands. (b) Transwell migration
assay of MDA-MB 231 MT1-MMP cells incubated in SF media for 12 hours. Migration is
shown as the percentage of migrated cells relative to MDA-MB 231 cells ± SEM. (c) Viability of
MDA-MB 231 MT1-MMP cell lines during incubation in media containing 10% FBS (top) or
serum free media (bottom) measured daily for 7 days using Celltiter96®. Viability is displayed
as mean optical density (O.D) at 490 nm ± SEM.
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active MT1-MMP, and with their higher migration levels relative to the other MDA-MB 231
MT1-MMP cell lines. Taken together these analyses show that naturally increased MT1-MMP
expression in transformed cancer cells (MDAMB-231, HS578t cells) does result in enhanced
migration, but this is not the case for experimental MT1-MMP overexpression (MCF-7 MT1MMP cell lines), as increasing overexpression of MT1-MMP decreases rather than enhances the
migratory potential of breast cancer cells.
Furthermore, the levels of MMP-2 and -9 produced by MDA-MB 231 cells were
analyzed via gelatin zymography and qPCR to determine if MT1-MMP overexpression affected
the expression of these genes (fig 20). Gelatin zymography analysis was conducted to assay
MMP-2 and -9 protein levels after MT1-MMP MDA-MB 231 cell lines were incubated with
serum-free media or MMP-2 CM for 12 hours. This analysis demonstrated that MT1-MMP
MDA-MB 231 cell lines were capable of activating proMMP-2, particularly C1 and C2 MDAMB 231 cells that facilitated the transition to the intermediate and active forms of proMMP-2
(fig 20a). Interestingly, MDA-MB 231 C1 cells, which express the highest level of MT1-MMP
and demonstrated the highest ability to activate proMMP-2, were completely devoid of MMP-9
protein production (fig 20a, red asterisk). This observation was confirmed at the mRNA level
using qPCR analysis, which demonstrated a significant change in MMP-2 and -9 levels in C1
and C2 MDA-MB 231 cells, particularly C1 cells which demonstrated a significant decrease in
MMP-9 expression and concurrent increase in MMP-2 expression (fig 20b), consistent with my
previous observations regarding MMP-2/-9 levels and MT1-MMP-mediated ERK activation
(figs 11,12).
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Figure 20. Overexpression of MT1-MMP in MDA-MB 231 cells permitted proMMP-2
activation and reciprocally affected MMP-2/-9 levels.
(a) Gelatin zymography analysis of MDA-MB 231 MT1-MMP cell lines after being incubated
for 24 hours in serum-free media (top) or serum-free media containing MMP-2 CM (bottom).
Red asterisks show a clear deficiency in MMP-9 protein from MDA-MB 231 C1 cells that
express the highest level of MT1-MMP. (b) qPCR analysis of MMP-2 and MMP-9 mRNA levels
from MDA-MB 231 MT1-MMP cell lines. mRNA levels are displayed as mean fold change
relative to MDA-MB 231 cells ± SEM.
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3.5 Low level of MT1-MMP expression mediated a protrusive
phenotype in 3D culture
As my work using in vitro 2D culture demonstrated that increased, but relatively low
levels of MT1-MMP expression were optimal for enhanced viability and migration, I
subsequently examined how these observations translated to ex vivo 3D culture. In this culture
system breast cancer cells are embedded in Matrigel, whose composition resembles the
components of a natural BM, and as such mimics a more physiologically relevant 3D
environment [107]. MCF-7 MT1-MMP cell lines were embedded in Matrigel and cultured for 5
days in media containing 10% FBS. During this time, cell morphology was monitored using DIC
microscopy to examine how MT1-MMP expression affected cell behavior during 3D culture.
Non-invasive MCF-7 cells have been shown to form and remain in circular colonies during 3D
culture [120] (see fig 22, white arrow), which resemble the acini-like structures that normal
breast cells form that are representative of the terminal ductal lobular unit (TDLU) in the human
breast [121]. In contrast, invasive cells, such as MDA-MB 231 cells lose this circular
morphology and develop into an interconnected network within the Matrigel (see fig 25, red
arrow).
During 3D culture, C1, C2 and C3 cells do not form an interconnect network as seen with
MDA-MB 231 cells. Instead, their colonies remained circular but displayed two distinct
phenotypes; disseminations - distinct particles being released from circular colonies (fig 21,
green arrow), and short dynamic protrusions emerging from colonies (fig 21, red arrows),
which were confirmed using time-lapse microscopy (videos 6-9). Comparison of the
morphological features between cell lines was performed by quantifying the number of
disseminations and protrusions over a span of 5 days per 10x magnification fields of view and
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Figure 21. MCF-7 MT1-MMP cell lines demonstrated two distinct morphologies during
Matrigel 3D culture.
MCF-7 and MT1-MMP cell lines were embedded in 50% Matrigel and incubated for 5 days in
media containing 10% FBS. Between days 2 and 5, samples were placed in a live imaging
chamber and imaged at 20x magnification at the same stage position every 30 minutes for 72
hours to make timelapse movies showing cell dynamics in 3D culture (See videos 6-9). Shown
are stills at three different time points for each sample that demonstrate two distinct
morphologies of MT1-MMP expressing cells during 3D culture. White arrows show a noninvasive circular morphology of MCF-7 cells, green arrows show a dissemination morphology
whereby there is a release of cell fragments from circular colonies, and red arrows display
dynamic protrusions emerging from colonies. Scale bars = 100 μm.
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normalizing it to the number of circular colonies per field of view (fig 22). This quantification
demonstrated that MCF-7 cells expressing high levels of MT1-MMP (C1 and C2) had
significantly higher number of disseminations per colony than parental MCF-7 and C3 cells,
particularly C1 cells which showed a time-dependent release of particles (video 7). In contrast,
the number of protrusions per colony at day 5 was inversely proportional to MT1-MMP levels,
as C2, and especially C3 cells had significantly more protrusions per colony, whereas C1 cells
had a significantly lower number of protrusions than MCF-7 cells. Immunofluorescence analysis
of these MCF-7 MT1-MMP cell lines (fig 23), confirmed that while MCF-7 colonies retained
circularity during 3D culture (white arrows), C1 and C2 cells had clear disorganization of colony
structure with released cell fragments (disseminations) containing MT1-MMP protein (green
arrows). In contrast, C3 cells demonstrated long F-actin protrusions emerging from circular
colonies (red arrows), consistent with the protrusive phenotype.
To further characterize this novel dissemination phenotype mediated by MT1-MMP, the
cellular composition of released fragments was examined by repeating the immunofluorescence
analysis with the MCF-7 zsGreen tagged cells (fig 24). The fluorescently tagged variants were
used to provide information about the origin of morphological structures as zsGreen accumulated
in the cytoplasm and could be used to better visualize the origins of disseminations or
protrusions. The number of single cells (marked by DAPI), F-actin disseminations, F-actin
protrusions, and zsGreen protrusions were quantified per colony from 20x magnification 3D
volume views (fig 24a). This quantification demonstrated that the disseminations are likely
enucleated cells, as C1 cells show significantly higher levels of single cells (0.18/colony) and Factin disseminations (0.67/colony) (fig 24b), which added together represented a density of
~0.85/colony, similar to the ~1 dissemination/colony seen by day 5 in the DIC microscopy
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Figure 22. MT1-MMP levels in MCF-7 cells correlated with a dissemination morphology
and were inversely correlated with a protrusive morphology in 3D culture.
(top) MCF-7 MT1-MMP cells were embedded in Matrigel and imaged every day for 5 days at
10x magnification. Shown is a representative field of view of each cell line at days 1, 3 and 5,
and indicated inset images at day 5 which show the cell features quantified: Circular colonies
(white arrow), disseminations around colonies (green arrow), or protrusions emanating from
colonies (red arrows). Scale bars = 100 μm. (Bottom line graphs) Five z-stacks per cell line were
acquired every day for 5 days and disseminations and protrusions were quantified per colony for
each cell line. Morphologies are displayed as mean dissemination/protrusion per colony ± SEM.
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Figure 23. High level of MT1-MMP expression causes loss of colony organization and
dissemination release in MCF-7 cells during 3D culture.
Representative 3D volume views of immunofluorescence analysis after MCF-7 MT1-MMP cells
were embedded in Matrigel for 5 days. Samples were imaged using confocal microscopy at 60x
and are displayed as an overlay (top) showing nuclei (blue), F-actin (red), and MT1-MMP signal
(green), and the respective individual channels below. Scale bars = 100 μm. White arrow show
circular colonies. Green arrows identify single cells that disseminated from the nearby colonies
and show MT1-MMP protein. Red arrow indicates an F-actin protrusion emanating from a
circular colony of MCF-7 cells expressing low levels of MT1-MMP.
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Figure 24. High levels of MT1-MMP correlated with a dissemination phenotype while low
levels of MT1-MMP correlated with a protrusive morphology in zsGreen MCF-7 cells
during 3D culture.
(a) MCF-7 and MT1-MMP cell lines stably expressing zsGreen were embedded in 50% Matrigel
for 5 days and processed for immunofluorescence to visualize nuclei, zsGreen protein, MT1MMP protein and F-actin distribution. Samples were imaged using confocal microscopy at 20x
magnification and displayed as a 3D volume overlay and the individual channels. Green boxes
indicate single cells adjacent to a colony, white boxes highlight the magnified insets on the right
showing F-actin disseminations (green arrows) and F-actin protrusions (red arrows). Scale bars =
100 μm. (b) Single cells, F-actin disseminations, F-actin protrusions, and zsGreen protrusions
were quantified from 20x magnification 3D volumes acquired after MCF-7 MT1-MMP cell lines
stably expressing zsGreen were embedded in Matrigel for 5 days. The representative 60x
magnification 3D volume of MT1-MMP C3 cells on the right shows both F-actin (red arrow) and
zsGreen (blue arrow) protrusions emerging from a colony. Scale bars = 100 μm.

88

analysis (fig 22). In contrast, C3 cells demonstrate higher density of F-actin (0.65/colony) and
zsGreen protrusions (0.15/colony), which when added together represent a density of
~0.8/colony similar to the ~1 protrusion/colony seen by day 5 in the DIC analysis, confirming
that these cells demonstrate a protrusive morphology in 3D culture. Volume views at 60x
magnification also showed C3 colonies (fig 24b, right) that demonstrated many zsGreen
protrusions (blue arrow) that emerged distal to existing F-actin protrusions (red arrow). These
protrusions are indicative of invadopodia, which are characterized by extension of the cell body
due to F-actin polymerization, and subsequent F-actin retraction to result in a protrusion devoid
of F-actin [66].
To corroborate my 3D observations with the MCF-7, C1, C2 and C3 cell lines, I
performed a similar analysis with MDA-MB 231 MT1-MMP cell lines (fig 25). Parental MDAMB 231 cells progressively lost circular morphology and developed into an interconnecting
network of cells within the Matrigel (fig 25, red arrow), represented by a significantly higher
number of protrusions per colony (~25) than MCF-7 cells. In contrast, all MDA-MB 231 cells
with elevated levels of MT1-MMP showed a significant inhibition to form networks in 3D
culture and instead retained a large proportion of circular colonies (fig 25, white arrows). As
well, MDA-MB 231 MT1-MMP cells demonstrated a nonsignificant increase in the number of
disseminations (~0.4 dissemination/colony), although it was comparatively lower than in MCF-7
MT1-MMP cells. Immunofluorescence analysis of F-actin and nuclear structures in 3D culture
confirmed these observations and showed that parental MDA-MB 231 cells formed an extensive
cellular network, whereas MDA-MB 231 MT1-MMP cells retained circular colonies marked by
MT1-MMP protein (fig 26). Taken together, this ex vivo analysis demonstrated that low MT1MMP expression mediated a protrusive phenotype in 3D culture, shown by MCF-7 C3 (fig 22)
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Figure 25. MT1-MMP overexpression inhibited the protrusive morphology of MDA-MB
231 breast cancer cells in 3D culture.
(a) (top) MDA-MB 231 MT1-MMP cells were embedded in Matrigel and imaged every day for
5 days at 10x magnification. Shown are representative fields of view of each cell line at days 1,3,
and 5 and a respective inset at day 5. Red arrow shows a portion of the protrusive network
MDA-MB 231 cells form in 3D culture. White arrows show MDA-MB 231 MT1-MMP cell
colonies that have retained circularity after 5 days in 3D culture. Scale bars = 100 μm. (Bottom
line graphs) Five z-stacks per cell line were acquired every day for 5 days and disseminations
and protrusions were quantified per colony for each cell line. Morphologies are displayed as
mean dissemination/protrusion per colony ± SEM.

91

92

Figure 26. High levels of MT1-MMP mediated retention of a circular morphology of MDAMB 231 cells during 3D culture.
Representative 3D volume views of immunofluorescence analysis after MDA-MB 231 MT1MMP cells were embedded in Matrigel for 5 days. Samples were imaged using confocal
microscopy at 60x and are displayed as an overlay (top) showing nuclei (blue), F-actin (red), and
MT1-MMP signal (green), and the respective individual channels below. Scale bars = 100 μm.
Red arrow shows irregular network of MDA-MB 231 cells, whereas green arrows show circular
colonies in MDA-MB 231 MT1-MMP cell lines that are positive for MT1-MMP protein signal.
Scale bars = 100 μm.
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and MDA-MB 231 cells (fig 25), whereas high levels of MT1-MMP expression (C1, C2, and
MDA-MB 231 MT1-MMP C1, C2, and C3 cells) inhibited the ability to form protrusive
networks in 3D culture and instead resulted in abnormal release of cell fragments.

3.6 Low levels of MT1-MMP expression mediated tumour
vascularization and extravasation in vivo
Following 3D culture analysis, the in vivo implications of the in vitro observations were
examined by using ex ovo chicken embryos [122] and zsGreen expressing MCF-7 C1, C2, and
C3 cell lines. These cells, along with zsGreen MDA-MB 231 cells, were suspended in Matrigel
and implanted into the ChorioAllantoic Membrane (CAM) of day 9 ex ovo chicken embryos
[115]. Eight days post implantation the resulting xenograft was visualized using a fluorescent
stereoscope to assess vascularization of the formed tumour. No MCF-7 or C1 tumours were
scored as vascularized, and only a minority (2/14) of C2 tumours demonstrated vascularization
by vessels of the chicken embryo (fig 27). In contrast, the majority of C3 (14/15) and MDA-MB
231 (15/16) tumours were vascularized, shown by the presence of non-fluorescent vessels
present within a dissected zsGreen tumour (fig 28, white arrow).
The metastatic potential of these cell lines was subsequently examined by direct
intravenous injection of zsGreen MCF-7 C1, C2, and C3 cell lines into the vasculature of day 14
chicken embryos, followed by assessment of extravasation efficiency 24 hours post-injection
[109]. Extravasation is a necessary step that precedes metastatic colony formation and as such
has been shown to directly correlate with metastatic potential [11]. MCF-7 and C1 cells, which
express the highest level of MT1-MMP, demonstrate poor extravasation efficiency, as < 5% of
cells were able to extravasate after 24 hours (fig 29). C2 cells showed a higher but non-
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Figure 27. MCF-7 MT1-MMP C3 cells formed vascularized tumors when implanted onto
the avian embryo CAM.
MCF-7 MT1-MMP cell lines and MDA-MB 231 cells stably expressing zsGreen were implanted
into the CAM of day 9 ex ovo chicken embryos and visualized 8 days post –implantation using a
fluorescence stereoscope to analyze tumour vascularization. Displayed are representative bright
field images showing the area of implantation on the embryo, and respective fluorescent images
showing the zsGreen channel. The white boxes outline the magnified insets showing
vascularization of the MT1-MMP C3 and MDA-MB 231 tumours. Bar graph shows percentage
of tumours that were vascularized (N ≥ 11). Scale bars = 2 mm.
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Figure 28. Excision of vascularized tumours demonstrated internal blood vessels.
A tumour from MDA-MB 231 cells expressing zsGreen was excised from a chicken embryo 8
days post-implantation and imaged using brightfield and fluorescence microscopy. Vessels
within the tumour (white arrows) can be seen by the presence of blood (brightfield) and absence
of fluorescent signal (zsGreen), which indicate that these vessels originate from the chicken
embryo. Cutting this tumour in half and rotating the pieces to reveal the inside of the tumour
(black arrows) confirms internal vascularization. Scale bars= 2mm.
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Figure 29. MT1-MMP levels were inversely correlated to the extravasation efficiency of
MCF-7 breast cancer cells in vivo.
Representative 3D volume views at 20x magnification of MCF-7 MT1-MMP cells stably
expressing zsGreen 24 hours-post intravenous injection into the chicken embryo CAM
vasculature. Shown is an overlay displaying the zsGreen cells (green) and CAM vasculature and
underlying stromal vessels labeled using lectin-rhodamine (red), and the isolated zsGreen
channel. Scale bars = 100 μm. Bar graph shows quantification of extravasation efficiency of
MCF-7 MT1-MMP cell lines 24 hours post-injection ± SEM.
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significant increase in percentage of extravasated cells (~8%), whereas C3 cells, which express
low levels of MT1-MMP, displayed a significant increase in extravasation efficiency (~15%)
compared to all other MCF-7 cell lines. Orthogonal sections of extravasated C1 and C3 cells
acquired using confocal microscopy at 60x magnification showed that C1 cells are capable of
extravasating out of the CAM vasculature (fig 30) but display membrane blebbing (white
arrow) and cell fragment release (green arrow), reminiscent of the disseminations observed in
3D culture (fig 22). In contrast, C3 cells exhibited a uniform morphology as they extravasated
into the stromal space (blue arrows) and contained cell protrusions trailing from the CAM
capillary bed into the stroma (red arrow, video 10), suggesting that these cells formed
invadopodia in vivo.

3.8 Metastatic 21T breast epithelial cell line produces undetectable
levels of MT1-MMP protein
To extend and corroborate the observations that low levels of MT1-MMP are optimal to
promote metastatic features in 3D culture and in vivo, the level of MT1-MMP protein in the 21T
series cell lines was assayed via immunoblot (fig 31). These cells were isolated from a single
patient and represent a mammary tumour progression series that mimic specific and progressive
stages of breast cancer progression [111, 123], from atypical ductal hyperplasia (21PT-ADH), to
ductal carcinoma in situ (21NT – DCIS) to an invasive mammary carcinoma (21MT-1- IMC).
Assaying MT1-MMP protein levels in these cell lines demonstrated that ADH and DCIS variants
produced active MT1-MMP, with the non-invasive DCIS cells producing higher levels of MT1MMP protein. Direct comparison to the MCF-7 MT1-MMP cell lines showed that C1 and C2
cells produced more active MT1-MMP than 21T ADH or DCIS cells. In contrast, 21T MT-1
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Figure 30. MCF-7 cells expressing low levels of MT1-MMP demonstrated a uniform
protrusive morphology when extravasating in vivo.
Orthogonal views of Z-stacks acquired using confocal microscopy at 60x of MT1-MMP C1 and
C3 cells 24 hours post-injection showing the top of the CAM capillary bed (top) and the
underlying stroma (bottom). Extravasated MT1-MMP C1 cells display cell fragmentation (green
arrows) and membrane blebbing (white arrow), whereas MT1-MMP C3 cells extravasate to
below the CAM with uniform morphology (blue arrows) and are capable of forming discrete
invasive protrusions in the stroma (red arrow). Scale bars = 100 μm.
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Figure 31. Metastatic human 21T breast cancer cells showed undetectable levels of MT1MMP protein similar to MCF-7 C3 cells.
Protein lysate from human 21T breast cancer cell lines, which represent a progression series
from atypical ductal hyperplasia (21PT-ADH), to ductal carcinoma in situ (21NT – DCIS), to
invasive mammary carcinoma (21MT-1- IMC), were analyzed via immunoblot for MT1-MMP
protein levels along with the MCF-7 MT1-MMP cell lines. The blots were probed with either
AB6004 (top) or AB51074 (bottom) antibody and shown as the normal exposure and as
transformed versions to clearly show banding pattern. Asterisks indicate MT1-MMP isoforms
(green – pro- form, red- active form, orange – degradation forms). β-actin was used as a loading
control.
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cells, which represent an invasive mammary carcinoma, produced undetectable levels of MT1MMP protein as determined by immunoblot, similar to C3 cells. The 21MT-1 IMC cells have
been show to possess metastatic qualities in 3D culture and in vivo when compared to the noninvasive variants [111], consistent with my observations that low levels of MT1-MMP are
representative of metastatic breast cancer.
Taken together, the observations in my study demonstrate that low levels of MT1-MMP
expression are optimal for tumourigenicity and metastatic potential in vivo, and importantly, that
abnormally high MT1-MMP overexpression correlated with a decrease, rather than enhancement
of tumorigenic features (see schematic representation fig. 32).
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Figure 32. Schematic overview of MT1-MMP expression levels and associated changes in
substrate degradation and cell migration in 2D culture, phenotypes in 3D culture, and
tumourigenesis in vivo.
Schematic representation of the findings of this study showing cell phenotypes across 2D and
3D culture platforms and in vivo. Legend describing molecular components in diagrams is shown
at the top, and fold change relative to MCF-7 parental cells is in the brackets to the right of the
bolded titles. MT1-MMP deficient breast cancer cells, such as MCF-7 cells, are incapable of
proMMP-2 activation or ECM degradation, and show low migration and viability during serumfree incubation. These cells retain a circular morphology in 3D culture, and do not form
vascularized tumours nor display high extravasation efficiency in vivo. Cells expressing high
levels of MT1-MMP are capable of proMMP-2 activation and widespread ECM degradation,
have increased survivability to serum-free stress, but do not demonstrate increased migration in
2D experiments. In 3D culture, these cells demonstrate a dissemination morphology and cell
fragment release mediated by MT1-MMP. Despite MT1-MMP protein production and associated
substrate degradation, these cells are unable to form vascularized tumours or increase their
extravasation efficiency in vivo. Cells expressing low levels of MT1-MMP do not demonstrate
proMMP-2 activation or widespread ECM degradation, but do show increased migratory
potential, and high viability during serum-free incubation. These cells demonstrate a protrusive
morphology in 3D culture, form vascularized tumours in vivo, and have significantly increased
extravasation efficiency, which are representative features of a metastatic phenotype.
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Chapter 4

4 Discussion
4.1 Low levels of MT1-MMP are optimal to mediate a metastatic
phenotype across various experimental platforms
In this study, I utilized overexpression of functional MT1-MMP in MCF-7 and MDAMB 231 breast cancer cells and demonstrated how high overexpression corresponds to proMMP2 activation and ECM degradation, but inversely correlates to migration and viability in 2D
culture, protrusive phenotype in 3D culture, and tumorigenic features in vivo. Instead I showed
that high overexpression of MT1-MMP negatively affects cell viability, and causes an abnormal
loss of colony structure and cell fragment release in 3D culture that translates to decreased
tumorigenic potential in vivo. I also demonstrated using the human 21T cell lines mammary
tumour progression series that breast cancer cells which mimic an invasive mammary carcinoma
(IMC) are better represented by low, rather than high, levels of MT1-MMP protein. My data is at
odds with the notion that high MT1-MMP expression is crucial for tumour progression, as
numerous studies report that MT1-MMP overexpression is associated with enhanced migratory
ability and tumourigenicity [40, 41, 49, 70, 95, 98], including increased cell migration [98],
metastatic potential [40, 41], and tumor/metastasis volume [49]; although there is also evidence
in agreement with my study which shows that high MT1-MMP overexpression is insufficient to
increase metastasis of human cancer cells [124]. Here, using MCF-7 clonal cell lines stably
expressing untagged MT1-MMP, I showed that migration, as shown by a scratch closure assay
and by time-lapse microscopy of cells on fluorescent substrate, is dependent on levels of MT1109

MMP, with high levels decreasing migratory ability and low levels promoting it. I also
demonstrated that MT1-MMP-mediated migration changes seen using transwell assays involve a
substantial cell viability component, where high MT1-MMP overexpression negatively affects
viability and low levels enhances it. This viability difference likely contributed to the magnitude
of migration augmentation between transwell and other assays. Studies that show an increase in
cancer cell migration as a result of MT1-MMP overexpression demonstrate migration
enhancement ranging from 50 -500% [31, 49, 98], whereas others show a requirement of TIMP2 for MT1-MMP mediated migration enhancement [99, 116]. These reports do not agree on a
specific mechanism, except general ERK activation. In contrast, there are studies demonstrating
that MT1-MMP overexpression does not increase migration of breast cancer cells [73], and also
that MT1-MMP overexpression decreases ERK activation in cancer cells [96]. In the latter study,
the authors demonstrated that MT1-MMP overexpression in various cancer cell lines, including
MCF-7 cells, downregulates ERK activation and migration in response to FGF-2, which is
consistent with my findings using cells that express high levels of MT1-MMP. Other studies
have provided strong mechanistic evidence that MT1-MMP is involved in apoptosis protection
[100] and viability enhancement via HIF1α stabilization [50, 104], which are in line with my
observations that MT1-MMP enhances viability during serum-free incubation.
In this study I also discovered a novel inverse transcriptional relationship between MMP2 and -9 mediated by the ERK pathway in MT1-MMP expressing cancer cells. Using the MCF-7
and MDA-MB231 MT1-MMP stable cell lines, and MDA-MB 231 and HS578t parental cells, I
showed that ERK phosphorylation in MT1-MMP positive breast cancer cells correlates with an
increase in MMP-9 levels and concomitant decrease in MMP-2 levels. An important aspect of
this relationship is that regardless of the level of ERK phosphorylation, one of these gelatinases
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is elevated in breast cancer cells that produce MT1-MMP. Myself and recently graduated MSc
Caitlin Evered used MDA-MB 231 cells to show that ERK inhibition causes changes in MMP-2
and -9 transcription as shown by luciferase reporter assays, and also decreased the migration of
these cells in 2D culture, and inhibited a protrusive phenotype in 3D culture, despite increased
expression of MMP-2 [125]. These data are consistent with my study in that increased MMP
expression, which is assumed to be accompanied by increased MMP activity, does not always
correlate with the promotion of metastatic features.
Despite the mounting evidence demonstrating that MMPs have a direct role in basement
membrane degradation in vitro, there is no evidence to date that shows this is the case in vivo
during cancer progression, or during development where MMPs are thought to be critical for
ECM remodeling and embryo patterning [19]. During C. elegans larval development, the uterine
and vulval tissues are initially separated by epidermal basement membranes, which needs to be
breached by a specialized cell, the anchor cell, for development to progress normally [126]. A
gene necessary for anchor cell invasion is the C. elegans Fos transcription factor orthologue, fos1a, for which mutations results in invadopodia that fail to breach the basement membrane [127].
One of the genes regulated by FOS-1A is zmp-1, a member of the MMP family in C. elegans,
implying a role for MMPs in anchor cell invasion [128]. However, animals that contain a
mutation in zmp-1 do not have defects in anchor cell invasion, which shows that ZMP-1 may not
be necessary for this particular process during C. elegans development [127, 128]. Follow-up
work demonstrated that during anchor cell invasion, the basement membrane was moved aside
by the invasive protrusion of the anchor cells, rather than being dissolved [129]. During mouse
development, the maternal uterus spatially restricts the growing embryo, causing an increase in
mechanical stress at the distal tip of the forming embryo, where basement membrane breaching
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occurs [130]. These breaches allow early epiblast cells to migrate through the gaps in the
basement membrane and form the distal visceral endoderm, a group of cells that are necessary to
establish the anterior-posterior axis during development [130, 131]. During this basement
membrane breaching process, it has been shown that MMPs are not expressed at the distal tip of
the embryo and fluorescent protease reporters were not active, demonstrating that MMPs are not
required for basement membrane disruption during mouse embryo development, and instead
suggests a predominant role for mechanical force in basement membrane breaching during this
process [131].
The Drosophila developmental model is also a useful platform to study MMP function as
it contains only two MMPs, Mmp1 and Mmp2, one which is secreted and the other is membrane
bound, and that contain the canonical MMP structure but have no direct human MMP
orthologues [132, 133]. During Drosophila development, cells of the outer squamous peripodial
epithelium and stalk (PS) invade the underlying larval epidermis by breaking through the
basement membrane [134]. This invasive process clears a path through the larval epidermis for
disc eversion and formation of adult structures, such as the wing. Hypomorphic mutants in both
Mmp1 and Mmp2 leads to maintenance of type IV collagen in the Drosophila embryo [135],
indicating that MMPs promote basement membrane removal during eversion, thereby
establishing a role for MMPs in basement membrane loss. However, whether the MMPs remove
basement membrane through bulk dissolution, limited proteolysis, or other mechanisms, remains
unclear. In disc eversion as in tumour development, where MMPS are thought to function as
ECM remodelers, the interactions between cells and the matrix that lead to basement membrane
removal have not yet been visualized, and recent observations suggest that the role of MMPs
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during basement membrane traversion may be related to proteolysis of non-ECM components or
induction of mechanical force, rather than solely the degradation of the ECM.
Consistent with aforementioned observations that basement membrane traversion may
not require ECM degradation mediated by MMPs are the observations seen in my
physiologically relevant ex vivo and in vivo experiments. In these experimental platforms I
showed that MCF-7 cells expressing low levels of MT1-MMP (C3) demonstrated metastatic
qualities in Matrigel 3D culture and in vivo, despite not demonstrating ability for proMMP-2
activation and widespread ECM degradation. C3 cells have increased protrusive morphology in
3D culture and this is contrasted with MCF-7 cells overexpressing high levels of MT1-MMP
which show reduced protrusive ability and increased cell fragmentation. Similarly, C3 cells were
tumorigenic and showed metastatic potential in vivo, unlike C1 and C2 cells, which is consistent
with studies that knock down MT1-MMP expression and show inhibited tumourigenesis and
metastasis. Importantly, I demonstrated that C3 cells have high extravasation efficiency in vivo
after direct injection into the CAM vessels of day 13 chicken embryos when the vasculature has
developed a basement membrane [136]. During extravasation, cells need to traverse the
basement membrane, and my results show that C3 cells (low MT1-MMP levels and activity),
rather than C1 or C2 cells (high MT1-MMP levels and activity), demonstrated increased ability
to extravasate, which shows that ECM degradation is not correlated to basement membrane
traversion and instead may be inhibitory if excessive. Furthermore, high magnification confocal
analysis (fig 30) and real time imaging (video 10) showed that C3 cells formed cellular
protrusions when extravasating in vivo, consistent with the protrusive morphology in 3D culture,
and suggesting that MT1-MMP may instead generate invasive protrusions that breach the
basement membrane via mechanical force.
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Analysis of MT1-MMP protein levels in the 21T cell lines mammary tumour progression
series demonstrated that breast cancer cells which represent early stage ADH and DCIS
mammary tumours produce high levels of active MT1-MMP protein, whereas invasive 21MT-1
IMC cells produce undetectable levels of MT1-MMP, an observation that is consistent with my
findings using MCF-7 C3 cells and my overall conclusion that low levels of MT1-MMP may
better represent metastatic cancer. A similar study using the HMT-3522 epithelial cell series
yielded results consistent with my analysis of MT1-MMP levels in 21T cells, as these authors
analyzed microarray data to show that MMP-9, -13,-15 and -17, but not MT1-MMP, were
functionally significant in the acquisition of invasiveness [137].
Interestingly, the observation that DCIS 21T cells produced high levels of active MT1MMP in comparison to their IMC counterparts is similar to the 3D culture phenotype of the
MDA-MB 231 cells overexpressing MT1-MMP. In this study, parental MDA-MB 231 cells,
which are naturally invasive, readily form irregular networks in 3D culture in contrast to noninvasive cell lines that partially maintain polarity and form acini similar to the TDLU in the
human breast (eg MCF-7 cells). It was surprising that overexpression of MT1-MMP in invasive
MDA-MB 231 cells reverted their phenotype in 3D culture towards a DCIS-like morphology
where the ability to form networks in matrigel 3D culture was restricted and a higher proportion
of these cells retain acini-like colonies. The reversion of MDA-MB 231 cells to a DCIS-like
phenotype in 3D culture as a result of MT1-MMP overexpression is consistent with the analysis
of MT1-MMP protein levels in the 21T cell lines, whereby DCIS (21NT) cells produce more
active MT1-MMP and predominantly form acini in 3D culture, and IMC (21MT-1) cells produce
less MT1-MMP protein and display invasive 3D behavior [111], similar to MT1-MMP MDAMB 231 cells and parental MDA-MB 231 cells, respectively.
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4.2 Inhibited MT1-MMP correlates with increased cell migration and
viability in 2D culture
A striking finding of my in vitro analysis regarding the relationship between MT1-MMP
expression and migration was that the most migratory cells were the ones which had a low MT1MMP:high TIMP-2 ratio. Of the MCF-7 MT1-MMP cell lines used, C3 and C3 SH 1 cells
displayed low MT1-MMP levels (11 and 1.8 fold change vs parental MCF-7 cells, respectively),
and their migration ability was greatly enhanced when the levels of TIMP-2 increased, especially
C3 SH 1 cells. MDA-MB 231 MT1-MMP cell lines displayed the same trend whereby MT1MMP overexpression with no change in TIMP-2 expression (data not shown) shifted the ratio in
favor of excess MT1-MMP, leading to uncontrolled proMMP-2 activation and ECM
degradation, and thereby causing a decrease in migratory potential and viability. Similarly,
analysis of the natural migration potential of MCF-7, MDA-MB 231, and HS578t cells is
consistent with this relationship to TIMP-2, as HS578t cells were the most migratory and
displayed the highest level of TIMP-2 expression relative to MT1-MMP. Noteworthy in this
analysis was also the observation that MDA-MB 231 cells displayed the highest ERK activation,
but were not the most migratory. This was consistent with the comparison of MCF-7 C2 and C3
cells, whereby C2 cells showed the highest ERK activation but were less migratory than C3
cells, which displayed comparatively lower ERK activation even in the presence of high levels of
TIMP-2.
Although TIMP-2 is a natural MMP inhibitor and as such has attracted therapeutic
interest along with synthetic MMP inhibitors [87-89, 94, 138, 139], neither have shown value in
clinical trials [93]. Instead, some have suggested that high TIMP-2 levels may promote
tumourigenicity [37, 99, 140], which has been strengthened by the association of high TIMP-2
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levels with poor prognosis in various human cancers, including breast [44, 45, 47, 141-143].
Although this association between an MMP inhibitor and poor cancer prognosis may be
paradoxical, I describe here that while TIMP-2 regulation of MT1-MMP activity is complex, as
exemplified by MDA-MB 231 and HS578t cells, high TIMP-2:low MT1-MMP ratios in these
cells correlate with their migratory potential, and also with their low proMMP activation ability
and lack of gelatin degradation. Despite the fact that MDA-MB 231 and HS578t cells naturally
express MT1-MMP, MMP-2, and -9, the extracellular gelatinases are predominantly found in
their pro-forms yet to be activated. As MT1-MMP activity is pivotal in gelatinase activation [85],
this indicates that MT1-MMP present in these cells is inhibited, likely by TIMP-2. This is
consistent with lack of gelatinase activity of C3 cells, and in stark contrast to C1 and C2 cells,
suggesting that cells with non-physiologically high MT1-MMP levels but low TIMP-2 levels
(which is not typical of cancers) exhibit excessive proteolysis which may be counterproductive
to migration and cell viability. This is corroborated both with the rescued serum free viability
and migration of C1 cells as a result of BB94 treatment, and with the role of TIMP-2 in
mediating survivability under serum free conditions as shown by others [100]. Since MT1-MMP
is a proteolytic enzyme that can cleave and alter the function of many ECM and non-ECM
proteins crucial for proper cell behavior [22], it is logical that such a potent protease with wide
substrate specificity would be under tight control by TIMP-2 to appropriately mediate cell
behaviour.

4.3 Immunological detection of human MMPs is unreliable
Recently Maden and Bugge (2015) analyzed the last two decades of literature to examine
if there was a consensus regarding the cellular source of MMPs (including MT1-MMP) in human
cancers and whether they were predominantly stromal or cancer cell derived [78]. These authors
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noted that publications were widely inconsistent in regards to the cellular source of MMPs,
particularly when immunodetection was involved. Only when in situ hybridization was used was
there a consensus seen that MMPs were likely stromal cell derived. The authors proposed
reasons for these difficulties, one being that there is likely inherently low expression of MMPs in
cancer cells compared to stromal cells making immunodetection technically challenging.
I believe that unreliable immunodetection reagents (discussed in [144]) is a major
contributing reason as to why there is such inconsistency when assessing the abundance of
MMPs in human cancers and their value as prognostic markers. In this study, I initially
experienced difficulties assessing immunoblots for MT1-MMP, which could only be correctly
interpreted after examining the immunological banding pattern for MT1-MMP expressing MCF7 and MDAMB-231 cell lines, and probing with two different primary antibodies against human
MT1-MMP (fig 33). To strengthen the idea that improper immunodetection of MT1-MMP
protein can lead to incorrect conclusions, I highlight my (lack of) immunodetection of MT1MMP in MCF-7 breast cancer cells. I strongly believe, as supported by my data, and as
suggested by others, that MCF-7 cells are MT1-MMP deficient [40, 99], particularly because it
has been shown that the MT1-MMP promoter in these cells is hypermethylated and thus
transcriptionally repressed [106]. Yet despite this observation, published studies claim to detect
both pro- and active MT1-MMP protein via immunoblot in MCF-7 cells [41, 145], which could
be due to incorrect identification of the cell line used for experimentation, or lack of stringency
when conducting immunodetection. As can be seen from my immunoblot data, usage of a
polyclonal antibody against MT1-MMP resulted in a non-specific signal that could easily be
misinterpreted as pro- and active MT1-MMP in MCF-7 cells (fig 33, AB6004). Furthermore, in
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Figure 33. Immunological detection of MT1-MMP protein can be confounding depending
on antibody utilized.
(a) Immunoblot analysis of MCF-7 and MDA-MB 231 MT1-MMP cell lines (top), or MCF-7,
MDA-MB 231 and HS578t breast cancer cell lines (bottom) using a polyclonal anti-MT1-MMP
rabbit antibody (AB6004 – Millipore). (b) Immunoblot analysis of MCF-7, MDA-MB 231, and
HS578t breast cancer cells, along with the MCF-7 MT1-MMP cell lines, using a monoclonal
rabbit antibody (AB51075- Abcam). These blots were ran for 6 hours at 140 volts on a 15%
acrylamide gel to ensure optimal band separation. On the left is a normal exposure of each blot
and on the left is transformed version to clearly demonstrate banding pattern. Arrows indicate
non-specific signal, whereas asterisks indicate specific signal pertaining to MT1-MMP isoforms
(green – pro- form, red- active form, orange – degradation forms). Note the substantial amount of
non-specific signal obtained when using AB6004 compared to AB51074, despite both antibodies
being able to specifically detect multiple isoforms of MT1-MMP. Of particular interest are the
red and green non-specific bands obtained using AB6004, which could be misinterpreted as proand active forms of MT1-MMP, respectively (see banding pattern for MT1-MMP deficient
MCF-7 cells).
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the study done by Köhrmann et al. (2009), although the authors reported MT1-MMP protein in
MCF-7 cells, they were not able to detect MT1-MMP protein from tumour samples via
immunoblot, despite showing increased MT1-MMP mRNA in these samples compared to
normal breast tissue [41]. However, these authors were able to detect MT1-MMP protein using
histology in tissue sections from tumour samples and not from normal tissues. Studies such as
this that are internally inconsistent regarding MT1-MMP protein detection, and when containing
clinical samples, can create confounding conclusions regarding the role of MMPs in cancer. This
is in agreement with the observations of Madsen and Bugge regarding the discrepancies of the
source of MMPs in human cancer, and the potential role of unreliable immunodetection when
examining MMPs, including MT1-MMP, in different human cancer tissue.
Additionally, visualizing MT1-MMP protein localization at a cellular level using
immunofluorescence may also lead to similar immunodetection problems. Lodillinsky et al.
(2016) recently implicated the p63/MT1-MMP axis in the transition from ductal carcinoma in
situ to metastatic breast cancer, reporting that MT1-MMP protein is present during BM invasion
of MCF10DCIS.com xenografts [59]. However, with the knowledge that MT1-MMP should be
localized to distinct specialized regions of the cell membrane to initiate invasion (invadopodia), I
question such immunofluorescence data that show MT1-MMP protein is present throughout the
cell membrane of every cell in the xenograft, regardless of whether it is in physical proximity to
invade the BM.
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4.4 Modest increase in MT1-MMP expression is physiologically
relevant in human cancer
To assess the physiological relevance of observed levels of MT1-MMP expression in this
study, I searched the literature for recently reported MT1-MMP mRNA levels in malignant
human breast tissue compared to non-malignant tissue. The reported increase in MT1-MMP
mRNA levels in malignant breast tissue compared to normal tissue ranged between ~1.7 to ~3.2
fold [48, 59, 64]. Similarly, a pioneering study used MDA-MB 231 variants that produced
constitutively active scr kinase, which is known to be upregulated during cancer progression
[66]. These MDA-MB 231 variants generated significantly more MT1-MMP containing
invadopodia. Analysis of MT1-MMP mRNA changes between control and constitutively active
src kinase cells demonstrated a ~1.8 fold change increase in MT1-MMP mRNA, which the
authors describe as a mechanistically meaningful increase in MT1-MMP expression level.
Therefore, the physiological relevance of extreme changes in expression levels, such as ~17,000
fold change in MT1-MMP mRNA seen in transient transfectants, or ~1500 fold change in stable
cell lines, would be difficult to reconcile with primary human breast cancers which have a ~1.7
to 3.2 fold change in MT1-MMP mRNA compared to normal tissue. Additionally, in line with
the idea that immunological reagents of MT1-MMP may be unreliable, if normal non-malignant
tissues do not contain detectable levels of MT1-MMP [41, 70] and cancerous tissues demonstrate
only a ~1.7 to 3.2 fold increase in MT1-MMP mRNA, then is it reasonable that a transcriptional
increase of that magnitude would be difficult to immunodetect at the protein level.
Taken together, my study shows that a physiologically relevant increase in MT1-MMP
levels during metastatic breast cancer is a best represented by a 1.8 to 11-fold change compared
to normal tissue. Additionally, although abnormally high levels of MT1-MMP overexpression
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may not reflect those seen in primary breast cancers, there is still mechanistic value in this
approach, as utilized in this study to demonstrate the constancy of the TIMP-2 mediated
activation of proMMP-2 by MT1-MMP. With this work I challenge the long-standing view that
MMPs, particularly MT1-MMP, exert their role in cancer progression as proteases that
predominantly degrade ECM components to allow cancer cell invasion, and instead suggest a
subtle role for MT1-MMP in tumour progression as metastatic cancer appears to be better
represented by low levels of TIMP-2-inhibited MT1-MMP protein.
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Chapter 5

Conclusions
MT1-MMP is a multifunctional protease that can affect cell function via proteolytic and
non-proteolytic mechanisms, and it was presumed that high levels of MT1-MMP mediate
metastatic progression via ECM degradation. My findings that low levels of MT1-MMP are
physiologically relevant and correlate with a metastatic phenotype suggest that very high levels
MT1-MMP overexpression represents a non-relevant level of MT1-MMP expression during
cancer progression. Excessive ECM degradation mediated by high levels of MT1-MMP is not
permissive to cell migration and tumourigenesis, while low levels of MT1-MMP promote
extravasation and vascularization in vivo via increased cell migration and viability.
Future work could focus on the examination of the binding partners of MT1-MMP, and
their role in mediating the phenotypes of the cells utilized in this study. As well, an in-depth
analysis of changes in cell signaling cascades in cell overexpressing MT1-MMP should be
conducted to determine the mechanisms responsible for the phenotype of these cells.
Additionally, MT1-MMP expression should be knocked down in the cell lines overexpressing
high levels of MT1-MMP to determine if an invasive phenotype is rescued when the level of
MT1-MMP expression is reduced.
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Video Legends
Videos 1-4. Time-lapse analysis of ECM degradation and cell migration of MCF-7 MT1MMP cells. Parental MCF-7 (Video 1), and MT1-MMP C1, C2, and C3 (Videos 2, 3, 4,
respectively) cells stably expressing zsGreen (green) were seeded on Alexa594 gelatin coated
coverslips (red) and incubated in a live imaging chamber at 370C, 5 % CO2. Images were
acquired using a Leica DM16000 B fluorescent microscope. Frames were taken every 10
minutes for 20 hours and compiled into time-lapse movies using ImageJ. Representative stills of
each cell line at time 0 and 20 hours are shown in Figure 16a. Scale bars = 100 μm.

Videos 5. ADAPT workflow for automated analysis of cell migration. Shown is an example
of the ADAPT plugin and associated trajectory visualization of the MCF-7 MT1-MMP C2 video
(Video 3). Video 3 is shown as the overlay of zsGreen cells (green) and Alexa594 gelatin coating
(red), as well as the individual channels (top). The zsGreen channel was used for the ADAPT
analysis (bottom, left) to yield a trajectory visualization of individual cells from initial point of
tracking (bottom, right). Three videos from independent experiments were analyzed in this
manner and the trajectory visualization from each was used to quantify individual cell migration
after 20 hours. Cell migration data is compiled in Figure 16b. Scale bars = 100 μm.

Videos 6-9. Time-lapse analysis of 3D culture dynamics of MCF-7 MT1-MMP cells. Parental
MCF-7 (Video 6), and MT1-MMP C1, C2, and C3 (Videos 7, 8, 9, respectively) cells were
embedded in 50% matrigel and incubated in a live imaging chamber at 370C, 5 % CO2. Z-stacks
(100 μm, 5 μm slices) were acquired using a Leica DM16000 B microscope. Frames were taken
every 30 minutes for 72 hours and focal planes showing colony features with the greatest clarity
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were compiled into time-lapse movies using ImageJ. Representative stills of each cell line at
three different time points are shown in fig 19. Scale bars = 100 μm.

Video 10. Real-time intravital imaging of extravasated MCF-7 MT1-MMP C3 cells. MCF-7
MT1-MMP C3 cells stably expressing zsGreen (green) were injected intravenously into the
CAM vasculature of day 13 chicken embryos and imaged 24 hours post-injection after labeling
the vessels with lectin rhodamine (red). A movie in real-time was acquired using the resonant
scanner of a Nikon A1R+ confocal microscope. The focus of the microscope was moved
manually to show that a single C3 cells has extravasated from the CAM vasculature and shows a
protrusion into the stroma (devoid of lectin-rhodamine signal). Scale bar = 100 μm
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